




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07C 205/00, 67/02	A1	(11) International Publication Number: WO 98/29382 (43) International Publication Date: 9 July 1998 (09.07.98)
(21) International Application Number: PCT/US97/24203 (22) International Filing Date: 30 December 1997 (30.12.97) (30) Priority Data: 08/774,542 30 December 1996 (30.12.96) US (71) Applicant: VANDERBILT UNIVERSITY [US/US]; Suite 850, 101 21st Avenue South, Nashville, TN 37203 (US). (72) Inventors: MARNETT, Lawrence, J.; 5309 Camelot Court, Nashville, TN 37027 (US). KALGUTKAR, Amit, S.; Apartment D-4, 111 Acklen Park Drive, Nashville, TN 37203 (US). (74) Agent: ADLER, Benjamin, Aaron; McGregor & Adler, 8011 Candle Lane, Houston, TX 77071 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 <div style="text-align: center;">  (I) </div> (57) Abstract <p>The present invention provides a compound of formula (I), wherein R is selected from the group consisting of CH₃, CH₂CH₃, (CH₂)₂CH₃, (CH₂)₃CH₃, (CH₂)₄CH₃, (CH₂)₅CH₃, (CH₂)₆CH₃, (CH₂)₂O(CH₂)₃CH₃, CH₂HC=CH(CH₂)₃CH₃, CH₂C≡C(CH₂)₃CH₃, CCH₂C≡C(CH₂)₂CH₃, CH₂C≡C-CCH₂CH₃, CH₂C≡C-CH₃ and CH₂C≡CH; and R' is selected from the group consisting of CH₃, CF₃, CH₂Cl and CH₂Br or a pharmaceutically acceptable salt or hydrate thereof. Also provided is a method of inhibiting the synthesis of prostaglandin endoperoxide synthase-2 (PGHS-2) in a mammal.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2

10

BACKGROUND OF THE INVENTION

Field of the Invention

15 The present invention relates generally to the fields of molecular pharmacology and the biochemistry of inflammation. More specifically, the present invention relates to a selective 2-acyloxyphenylalkyl and 2-acyloxyphenylaryl sulfide inhibitors of prostaglandin endoperoxide synthase-2.

20 Description of the Related Art

Prostaglandins, particularly prostaglandin E₂ (PGE₂), are involved in many diverse physiological and pathophysiological functions. These eicosanoids are produced by the action of prostaglandin endoperoxide synthase (PGHS, EC 1.14.99.1) on
25 arachidonic acid. Prostaglandin endoperoxide synthase activity originates from two distinct and independently regulated isozymes, termed as prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 and are encoded by two different genes (1,2).


30 Prostaglandin endoperoxide synthase-1 is expressed constitutively and is thought to play a physiological role, particularly in platelet aggregation, cytoprotection in the stomach, and regulation of normal kidney function (Figure 1). Prostaglandin endoperoxide synthase-2 is the inducible isozyme
35 and expression of prostaglandin endoperoxide synthase-2 is induced by a variety of agents which include endotoxin, cytokines, and mitogens (2,3). Importantly, prostaglandin endoperoxide synthase-2 is induced *in vivo* in significant levels upon pro-inflammatory stimuli (4).

These discoveries led to the proposal that prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 serve different physiological and pathophysiological functions. For example, the disruption of beneficial prostaglandin production by all of the currently used non-steroidal antiinflammatory drugs (NSAIDs) results in a mechanism-based toxicity mainly in the gastrointestinal tract and kidney and thus limits their therapeutic usefulness especially when long-term treatment is involved (5-7). As a result of this critical finding, a major discovery effort has been executed in the pharmaceutical industry to identify selective and orally active prostaglandin endoperoxide synthase-2 inhibitors because they may provide the desired anti-inflammatory and analgesic properties without the deleterious and sometimes life threatening side effects commonly associated with the existing non-steroidal antiinflammatory drugs.

The prior art is deficient in the lack of selective and orally active prostaglandin endoperoxide synthase-2 inhibitors. The present invention fulfills this longstanding need and desire in the art.

SUMMARY OF THE INVENTION

In one embodiment of the present invention, there is provided a compound of the formula



(I)

wherein R is selected from the group consisting of CH₃, CH₂CH₃, (CH₂)₂CH₃, (CH₂)₃CH₃, (CH₂)₄CH₃, (CH₂)₅CH₃, (CH₂)₆CH₃, (CH₂)₂O(CH₂)₃CH₃, CH₂HC=CH(CH₂)₃CH₃, CH₂C≡C(CH₂)₃CH₃, CCH₂C≡C(CH₂)₂CH₃, CH₂C≡C-CCH₂CH₃, CH₂C≡C-CH₃ and CH₂C≡CH; and R' is selected from the group consisting of CH₃, CF₃, CH₂Cl and CH₂Br or a pharmaceutically acceptable salt or hydrate thereof.

In another embodiment of the present invention, there is provided a pharmaceutical composition, comprising the novel

compounds of the present invention and a pharmaceutically acceptable carrier.

In yet another embodiment of the present invention, there is provided a method of inhibiting the synthesis of prostaglandin endoperoxide synthase-2 (PGHS-2) in a mammal in need of such treatment, comprising the step of administering to said mammal an effective amount of a compound of Formula (I).

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

Figure 1 shows a schematic of the physiological stimuli which lead to inflammation.

Figure 2A shows the structures of flosulide, NS-398, SC 8076, aspirin and DuP 697. Figure 2B shows the synthetic scheme for the synthesis of compounds 2, 3, 4 and 6-14. Figure 2C shows the synthetic scheme for the synthesis of compounds 15, 16, 17, 18 and 19. Figure 2D shows the synthetic scheme for the synthesis of compounds 21, 22, 23, and 24. Figure 2E shows the synthetic scheme for the synthesis of compounds 26, 27, 28, 29, 30 and 31. Figure 2F shows the synthetic scheme for the synthesis of compounds 33-48 and 49-63. Figure 2G shows the synthetic scheme for the synthesis of compounds 65, 66, 67, 69, 70 and 71. Figure 2H shows the synthetic scheme for the synthesis of compounds 73, 74 and 75. Figure 2I shows the synthetic scheme for the synthesis of compounds 79-91. Figure

2J shows the synthetic scheme for the synthesis of compounds 36, 92, and 93. Figure 2K shows the synthetic scheme for the synthesis of compounds 95, 96 and 97.

Figure 3 shows the time- and concentration-dependent inhibition of human PGHS-2 and ovine PGHS-1 by 2-acetoxythioanisole (2). HoloPGHS-1 (22 nM) or holoPGHS-2 (88 nM) was incubated with the indicated concentrations of 2 for 3 hours at room temperature. Cyclooxygenase reaction was initiated by the addition of 50 μ M [1- 14 C]-arachidonic acid for 30 sec at 37°C. Closed squares, PGHS-2 + 2; open squares, PGHS-1 + 2. 2-Acetoxythioanisole (mM) % Remaining Enzyme

Figure 4 shows the time-dependent inhibition of the cyclooxygenase activity of Apo and HoloPGHS-2 by 2-Acetoxythioanisole (2). ApoPGHS-2 (5 μ M) or holoPGHS-2 (5 μ M) was incubated with a 1000-fold excess of 2. Periodic 0.16 μ M enzyme aliquots (final inhibitor concentration ~160 μ M) were analyzed for remaining cyclooxygenase or peroxidase activity as described above. Closed squares, cyclooxygenase activity of holoPGHS-2; open squares, cyclooxygenase activity of apoPGHS-2; closed circles, peroxidase activity of holoPGHS-2; open circles, peroxidase activity of apoPGHS-2.

Figure 5 shows the time- and concentration-dependent inhibition of human PGHS-2 and ovine PGHS-1 by aspirin. HoloPGHS-1 (22 nM) or holoPGHS-2 (88 nM) was incubated with the indicated concentrations of aspirin for 1 hour at room temperature. Cyclooxygenase activity was initiated by the addition of [1- 14 C]-arachidonic acid (50 μ M) for 30 sec at 37°C. Open squares, PGHS-1 + aspirin; closed squares, PGHS-2 + aspirin.

Figure 6 shows the inactivation of the cyclooxygenase activities of holo and apoPGHS-2 by 2-acetoxythioanisole (2). Apo or HoloPGHS-2 (5 μ M) was inactivated with a 1000-fold excess of 2-acetoxythioanisole (2) at 22.5°C in 100 mM Tris-HCl buffer, pH 8 containing 500 mM phenol for the indicated time period, and then hydroxyl amine (80 mM) in 10 mM Tris-HCl buffer, pH 7.5 was added as indicated (arrow). Periodic 0.16 μ M aliquots of holoPGHS-2 (open circles), holoPGHS-2 + 2-acetoxythioanisole (open squares), apoPGHS-2 (closed circles), apoPGHS-2 + 2-acetoxythioanisole (closed squares) were analyzed for cyclooxygenase activity.

Figure 7 shows the effect of pH on the inhibition of the cyclooxygenase activity of human PGHS-2 by 2-acetoxythioanisole (2). ApoPGHS-2 (5 μ M, 1.62 μ g/ μ L) in 100 mM sodium phosphate buffer of pH 6, 7, 8, and 9 was reconstituted with 2 equivalents of hematin. Compound 2 (1000-fold excess) in DMSO was added to the reaction mixture. Periodically, 0.16 μ M enzyme aliquots (final inhibitor concentration ~178 μ M) were analyzed for remaining cyclooxygenase activity. Open circles, cyclooxygenase activity of holoPGHS-2 treated with 2 at pH 6; closed circles, cyclooxygenase activity of holoPGHS-2 + 2 at pH 7; open squares, cyclooxygenase activity of holoPGHS-2 + 2 at pH 8; closed squares, cyclooxygenase activity of holoPGHS-2 + 2 at pH 9. Control experiments in the absence of inhibitor remained linear throughout the assay period.

Figure 8 shows the time- and concentration-dependent inhibition of human PGHS-2 and ovine PGHS-1 by 2-(Trifluoromethylacetoxy)thioanisole (6). HoloPGHS-1 (22 nM) or holoPGHS-2 (88 nM) was incubated with the indicated concentrations of 6 for 3 hours at room temperature. Cyclooxygenase reaction was initiated by the addition of [1- 14 C]-arachidonic acid (50 μ M) for 30 sec at 37°C. Open squares, PGHS-1 + 6; closed squares, PGHS-2 + 6.

Figure 9 shows the time- and concentration-dependent inhibition of human PGHS-2 and ovine PGHS-1 by 2-acetoxyphenyl heptyl sulfide (54) and a comparison with 2-Hydroxyphenylheptyl sulfide (38). HoloPGHS-1 (22 nM) or holoPGHS-2 (88 nM) was incubated with the indicated concentrations of 54 and 38 for 3 hours at room temp. Cyclooxygenase reaction was initiated by the addition of [1- 14 C]-arachidonic acid (50 μ M) for 30 seconds at 37°C. Closed squares, cyclooxygenase activity of holoPGHS-2 treated with 54; open squares, cyclooxygenase activity of holoPGHS-1 treated with 54; closed circles, cyclooxygenase activity of holoPGHS-2 treated with 38; open circles, cyclooxygenase activity of holoPGHS-1 treated with 38.

Figure 10 shows the effect of pH on the inhibition of the cyclooxygenase activity of human PGHS-2 by 2-Acetoxyphenylheptyl sulfide (54). ApoPGHS-2 (5 μ M, 1.62 μ g/ μ L) in 100 mM sodium phosphate buffer of pH 6, 7, 8, and 9 was reconstituted with 2 equivalents of hematin. Compound 54 (181

μM) in DMSO was added to the reaction mixture. Periodically, 0.16 μM enzyme aliquots (final inhibitor concentration $\sim 6 \mu\text{M}$) were analyzed for remaining cyclooxygenase activity. Open circles, cyclooxygenase activity of holoPGHS-2 treated with **54** at pH 6; closed circles, cyclooxygenase activity of holoPGHS-2 + **54** at pH 7; open squares, cyclooxygenase activity of holo PGHS-2 + **54** at pH 8; closed squares, cyclooxygenase activity of holoPGHS-2 + **54** at pH 9. Control experiments in the absence of inhibitor remained linear throughout the entire assay period.

Figure 11 shows the time-dependency and concentration-dependent inhibition of human PGHS-2 and ovine PGHS-1 by 2-Acetoxyphenyl-2-butoxyethyl sulfide (**67**) and 2-acetoxyphenyl-3-propionoxypropyl sulfide (**71**). HoloPGHS-2 (22 nM) or holoPGHS-1 (88 nM) was incubated with the indicated concentrations of **67** or **71** for 3 hours at room temperature. Cyclooxygenase reaction was initiated by the addition of $[1-^{14}\text{C}]$ -arachidonic acid (50 μM) for 30 sec at 37°C. Closed squares, cyclooxygenase activity of holoPGHS-2 treated with **67**; open squares, cyclooxygenase activity of holoPGHS-1 treated with **67**; open circles, cyclooxygenase activity of holoPGHS-1 treated with **71**; closed circles, cyclooxygenase activity of holoPGHS-2 treated with **71**.

Figure 12 shows the time- and concentration-dependent inhibition of human PGHS-2 and ovine PGHS-1 by 2-Acetoxyphenyl-2-butylpropargyl sulfide (**79**). HoloPGHS-1 (22 nM) or holoPGHS-2 (88 nM) was incubated with the indicated concentrations of **79** for 3 hours at room temperature. Cyclooxygenase activity was initiated by the addition of 50 μM $[1-^{14}\text{C}]$ -arachidonic acid for 30 sec at 37°C. Closed squares, cyclooxygenase activity of PGHS-2; open squares, cyclooxygenase activity of PGHS-1; closed triangles, cyclooxygenase activity of holoPGHS-2 treated with the corresponding 2-hydroxyphenyl-hept-2-ynyl sulfide (**78**).

Figure 13 shows the time and concentration dependent inhibition of human PGHS-2 and ovine PGHS-1 by 2-acetoxyphenylhex-2-ynyl sulfide (**88**). HoloPGHS-2 (22 nM) or holoPGHS-2 (88 nM) was incubated with the indicated concentrations of **88** for 3 hours at rt. Cyclooxygenase activity was initiated by the addition of 50 μM $[1-^{14}\text{C}]$ -arachidonic acid for

30 seconds at 37°C. Closed squares: cyclooxygenase activity of PGHS-2; open squares: cyclooxygenase activity of PGHS-1. Figure 14 shows the inhibition of PGHS-2 in activated macrophages by 2-acetoxythioanisole (2): comparison with aspirin. Figure 15 shows the inhibition of PGHS-2 in activated macrophages by 2-(Acetoxyphenyl) hept-2-ynyl Sulfide (87) and 2-(Acetoxyphenyl)heptyl Sulfide (54).

DETAILED DESCRIPTION OF THE INVENTION


Two general structural classes of prostaglandin endoperoxide synthase-2 selective inhibitors are commonly reported in the literature. In addition to selective prostaglandin endoperoxide synthase-2 inhibition *in vitro*, many of these compounds possess potent anti-inflammatory activity in the rat adjuvant-induced arthritis model along with exceptional safety profiles in comparison with the existing antiinflammatory agents. The structural classes include the tricyclic non-acidic arylmethyl sulfones (8-11) (exemplified by DuP 697 and SC 8092) and the acidic sulfonamides (12-15) (exemplified by Flosulide and NS-398) (Figure 2). The arylmethyl sulfonyl moiety in the tricyclic non-acidic compounds such as SC 8092 is thought to play a key role in the selective prostaglandin endoperoxide synthase-2 inhibition by these compounds as reduction of the sulfone group in SC 8092 to the corresponding sulfide functionality generates SC 8076, a prostaglandin endoperoxide synthase-1 selective inhibitor (11) (see Figure 2).

In the present invention, a variety of substituted acyloxybenzene derivatives were synthesized and examined as selective prostaglandin endoperoxide synthase-2 inhibitors. Introduction of a 2-methylthio functionality leads to the corresponding 2-acetoxythioanisole 2 derivative which displays selective inhibition of the cyclooxygenase activity of prostaglandin endoperoxide synthase-2 (IC_{50} (PGHS-2) ~ 264 μ M; IC_{50} (PGHS-1) > 5 mM).

Attempts to improve the potency of 2 as a prostaglandin endoperoxide synthase-2 selective inhibitor has led to the discovery of novel 2-acetoxyphenyl alkyl and aryl sulfides some of which are ~ 300 times more potent than 2 as

the present invention provides the discovery of a new structural class of selective prostaglandin endoperoxide synthase inhibitors. Subsequent inhibition studies with ^{14}C -radiolabeled inhibitors have established that selective prostaglandin endoperoxide synthase-2 inhibition arises from acetylation of an active site amino acid residue. The present invention is the first documentation of a selective covalent modification of prostaglandin endoperoxide synthase-2 by a selective prostaglandin endoperoxide synthase-2 inhibitor. In addition to the *in vitro* inhibition studies with purified human prostaglandin endoperoxide synthase-2 and ovine prostaglandin endoperoxide synthase-1, the ability of these new compounds in inhibiting prostaglandin endoperoxide synthase-2 activity in murine macrophages was also examined. Most of the inhibitors displayed potent inhibition of the prostaglandin endoperoxide synthase-2 activity in murine macrophages activated with LPS and IFN- γ indicating that these compounds are active *in vivo* as well.

The present invention is directed to a compound of the formula



(I)

wherein R is selected from the group consisting of CH_3 , CH_2CH_3 , $(\text{CH}_2)_2\text{CH}_3$, $(\text{CH}_2)_3\text{CH}_3$, $(\text{CH}_2)_4\text{CH}_3$, $(\text{CH}_2)_5\text{CH}_3$, $(\text{CH}_2)_6\text{CH}_3$, $(\text{CH}_2)_2\text{O}(\text{CH}_2)_3\text{CH}_3$, $\text{CH}_2\text{HC}=\text{CH}(\text{CH}_2)_3\text{CH}_3$, $\text{CH}_2\text{C}\equiv\text{C}(\text{CH}_2)_3\text{CH}_3$, $\text{CCH}_2\text{C}\equiv\text{C}(\text{CH}_2)_2\text{CH}_3$, $\text{CH}_2\text{C}\equiv\text{C}-\text{CCH}_2\text{CH}_3$, $\text{CH}_2\text{C}\equiv\text{C}-\text{CH}_3$ and $\text{CH}_2\text{C}\equiv\text{CH}$; and R' is selected from the group consisting of CH_3 , CF_3 , CH_2Cl and CH_2Br or a pharmaceutically acceptable salt or hydrate thereof. Preferably, the representative examples of compounds of the present invention are selected from the group consisting of 2-acetoxythioanisole, 2-(trifluoromethylacetoxy)thioanisole, 2-(α -chloroacetoxy)thioanisole, 2-(α -bromoacetoxy)thioanisole, 2-acetoxyphenylbenzyl sulfide, 2-acetoxyphenyl-2-phenylethyl sulfide, 2-acetoxyphenylethyl sulfide, 2-acetoxyphenylpropyl sulfide, 2-acetoxyphenylbutyl sulfide, 2-acetoxyphenylpentyl sulfide, 2-acetoxyphenylhexyl sulfide, 2-acetoxyphenylheptyl

sulfide, 2-acetoxyphenyl-2-butoxyethyl sulfide, 2-acetoxyphenyl-2-*trans*-heptenyl sulfide, 2-acetoxyphenylhept-2-ynyl sulfide, 2-acetoxyphenylhex-2-ynyl sulfide, 2-acetoxyphenylpent-2-ynyl sulfide, 2-acetoxyphenylbut-2-ynyl sulfide and 2-acetoxyphenylprop-2-ynyl sulfide, or pharmaceutically acceptable salts or hydrates thereof.

Compounds of Formula (I) are capable of inhibiting inducible proinflammatory proteins, such as cyclooxygenase-2 and are therefore useful in therapy. These proinflammatory lipid mediators of the cyclooxygenase (CO) pathway are produced by the inducible cyclooxygenase-2 enzyme. Regulation, therefore, of cyclooxygenase-2 which is responsible for these products derived from arachidonic acid, such as the prostaglandins affect a wide variety of cells and tissue states and conditions. Expression of cyclooxygenase-1 is not affected by the compounds of Formula (I). This selective inhibition of cyclooxygenase-2 may alleviate or spare ulcerogenic liability associated with inhibition of cyclooxygenase-1 thereby inhibiting prostaglandins essential for cytoprotective effects. Thus, inhibition of the proinflammatory mediators is of benefit in controlling, reducing and alleviating many of these disease states. Most notably, prostaglandins have been implicated in pain (such as in the sensitization of pain receptors) or edema. This aspect of pain management includes treatment of neuromuscular pain, headache, cancer pain and arthritis pain. Compounds of Formula (I) or a pharmaceutically acceptable salt thereof, are of use in the prophylaxis or therapy in a human, or other mammal, by inhibition of the synthesis of the cyclooxygenase-2 enzyme.

Accordingly, the present invention is also directed to a method of inhibiting the synthesis of prostaglandins by inhibition of prostaglandin endoperoxide synthase-2 (PGHS-2) in a mammal in need of such treatment, comprising the step of administering to said mammal an effective amount of a compound of Formula (I). Generally, this method is useful in the prophylaxis or therapeutic treatment of edema, fever, algesia, neuromuscular pain, headache, cancer pain or arthritic pain. Representative compounds useful in this method include 2-acetoxythioanisole, 2-(trifluoromethylacetoxy)thioanisole, 2-(α -chloroacetoxy)thioanisole, 2-(α -bromoacetoxy)thioanisole, 2-

acetoxyphenylbenzyl sulfide, 2-acetoxyphenyl-2-phenylethyl sulfide, 2-acetoxyphenylethyl sulfide, 2-acetoxyphenylpropyl sulfide, 2-acetoxyphenylbutyl sulfide, 2-acetoxyphenylpentyl sulfide, 2-acetoxyphenylhexyl sulfide, 2-acetoxyphenylheptyl sulfide, 2-acetoxyphenyl-2-butoxyethyl sulfide, 2-acetoxyphenyl-2-*trans*-heptenyl sulfide, 2-acetoxyphenylhept-2-ynyl sulfide, 2-acetoxyphenylhex-2-ynyl sulfide, 2-acetoxyphenylpent-2-ynyl sulfide, 2-acetoxyphenylbut-2-ynyl sulfide and 2-acetoxyphenylprop-2-ynyl sulfide, or pharmaceutically acceptable salts or hydrates thereof.

The present invention is also directed to a pharmaceutical composition, comprising a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent. In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non-toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.

Compounds of Formula (I), pharmaceutically acceptable salt thereof and pharmaceutical compositions incorporating such, may be conveniently administered by any of the routes conventionally used for drug administration, e.g., orally, topically, parenterally, or by inhalation. The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of the present invention may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well known variable. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The pharmaceutical carrier employed may be, for example, either a solid or a liquid. Representative solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Representative liquid carriers include syrup, peanut oil, olive oil, water and the like. Similarly, the carrier may include time delay material well known in the art such as glyceryl monostearate or glyceryl distearate alone or with a wax.

A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1 gram. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.

Compounds of Formula (I) may be administered topically (non-systemically). This includes the application of a compound externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the bloodstream. Formulation suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments, pastes and drops suitable for administration to the ear, eye and nose. The active ingredient may comprise, for topical administration from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the Formulation. It may however, comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the Formulation.

Lotions according to the present invention include those suitable for application to the skin and eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap, a mucilage, an oil of natural origin such as almond, corn, archis, castor, or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin may also be included.

Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (~0.002%), benzalkonium chloride (~0.01%) and chlorhexidine acetate (~0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

Compounds of formula (I) may be administered parenterally, i.e., by intravenous, intramuscular, subcutaneous, intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Compounds may also be administered

by inhalation, e.g., intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as aerosol formulation or a metered dose inhaler may be prepared by conventional techniques well known to those having ordinary skill in this art.

For all methods of use disclosed herein for the compounds of the present invention, the daily oral dosage regiment will preferably be from about 0.1 to about 100 mg/kg of total body weight. The daily parenteral dosage regiment will preferably be from about 0.1 to about 100 mg/kg of total body weight. The daily topical dosage regimen will preferably be from about 0.1 to about 15 mg, administered one to four, preferably two to three times daily. It will also be recognized by one of skill in this art that the optimal quantity and spacing of individual dosages of a compound of the present invention, or a pharmaceutically acceptable salt thereof, will be determined by the nature and extent of the condition being treated and that such optimums can be determined by conventional techniques.

Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety. Suitable pharmaceutically acceptable cations are well known in the art and include alkaline, alkaline earth ammonium and quaternary ammonium cations.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

EXAMPLE 1

Chemistry

Melting points were determined using a Gallenkamp melting point apparatus and are uncorrected. Tetrahydrofuran

(THF) was distilled from sodium benzophenone ketyl. Acetonitrile was distilled over calcium hydride. Unless stated otherwise, synthetic reactions were carried out under a argon atmosphere. All chemicals (Aldrich, Milwaukee, WI or Lancaster, PA) were reagent grade or better. ¹H NMR spectra were recorded on a Bruker WP-360 or AM 400 spectrometers; chemical shifts are expressed in parts per million relative to internal tetramethylsilane (TMS) standard and spin multiplicities are given as s (singlet), bs (broad singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), and m (multiplet). Fast atom bombardment mass spectra (FAB-MS) were recorded on a Kratos Concept II HH four sector mass spectrometer. Column chromatography was performed using silica gel (60-100 mesh) from fisher.

EXAMPLE 2

Synthesis of 2-Hydroxy-1-methylphenylsulfone (3)

To a reaction mixture containing 2-hydroxy-1-methylphenylmercaptan (1, 1 g, 7.13 mmol) in 20 mL of glacial acetic acid was added 30% H₂O₂ (14 mL) dropwise at 0°C. After the addition was complete, the reaction was warmed to 100°C and allowed to stir overnight. The mixture was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (EtOAc:pet ether; 90:10) and then recrystallized from EtOH / H₂O to afford 3 as a white crystalline solid in 52% yield: mp 95-97°C; ¹H NMR (CDCl₃) δ 8.85 (s, 1 H, OH), 7.67-7.71 (dd, 1 H, ArH), 7.51-7.56 (t, 1 H, ArH), 7.02-7.06 (m, 2 H, ArH), 3.13 (s, SO₂CH₃). FAB-MS 173 (MH⁺, 55), 157 (55), 93 (30), 79 (100) (Figure 2B).

2-Hydroxyphenylheptyl sulfone (92) was prepared in a similar manner as a colorless oil (137 mg, 62%). ¹H NMR (CDCl₃) δ 7.62-7.64 (dd, 1 H, ArH), 7.51-7.55 (t, 1 H, ArH), 7.01-7.05 (m, 2 H, ArH), 3.11-3.15 (t, 2 H, CH₂), 1.70-1.78 (m, 2 H, CH₂), 1.24-1.36 (m, 8 H, CH₂), 0.84-0.87 (t, 3 H, CH₃) (Figure 2J).

EXAMPLE 3

Acetylation of the Phenol Derivatives: Method A

A reaction mixture containing appropriate arenol (14.26 mmol) in 5 mL of acetic anhydride and 5 drops of H₃PO₄

was heated on a water bath for 15 min. Water (10 mL) was added dropwise to the hot reaction mixture which was then cooled in an ice-bath. The aqueous solution was extracted with CHCl_3 (3 x 30 mL). The combined organic extracts were washed with water, dried (MgSO_4), filtered, and the solvent was removed under vacuo to afford the crude product which was purified on silica gel with EtOAc:petroleum ether (10:90) to afford the desired product in near quantitative yields.

2-Acetoxy-1-methylphenylsulfone (4) White crystalline solid from EtOH / H_2O in 91% yield: mp 107-109 °C; ^1H NMR (CDCl_3) δ 8.01-8.04 (dd, 1 H, ArH), 7.65-7.68 (t, 1 H, ArH), 7.41-7.46 (t, 1 H, ArH), 7.25-7.28 (d, 1 H, ArH), 3.12 (s, 3 H, SO_2CH_3), 2.3 (s, 3 H, COCH_3) (Figure 2B).

2-Acetoxyanisole (5) Colorless oil in 78% yield. ^1H NMR (CDCl_3) δ 7.02-7.05 (t, 1H, ArH), 6.94-6.98 (m, 3 H, ArH), 3.83 (s, 3 H, CH_3), 2.31 (s, 3 H, CH_3); FAB-MS MH^+ 167 (100), 124 (60), 79 (80).

EXAMPLE 4

20 Acetylation of the Phenol Derivatives: Method B

A reaction mixture containing 2-mercaptomethylphenol (1, 0.3 g, 2.14 mmol) in 5 mL of CH_2Cl_2 was treated with dry pyridine (0.169 g, 2.2 mmol) and appropriate acid anhydride (2.14 mmol). The reaction mixture was stirred overnight and then diluted with water. The aqueous solution was extracted with Et_2O (3 x 10 mL). The combined organic solution was washed with water, dried (MgSO_4), filtered, and the solvent was removed under vacuo. The crude product was chromatographed on silica gel and eluted with EtOAc:petroleum ether (2:98) to afford the desired product. In this manner, 2-acyloxythioanisole analogs 6-14 were synthesized (see Figures 2B and 2C for chemical and physical properties of individual compounds).

2-Acetoxyphenylheptyl sulfone (93) colorless oil in 56 % yield. ^1H NMR (CDCl_3) δ 7.98-8.0 (dd, 1 H, ArH), 7.65-7.69 (t, 1 H, ArH), 7.41-7.45 (t, 1 H, ArH), 7.24-7.26 (d, 1 H, ArH), 3.21-3.25 (t, 2 H, CH_2), 2.37 (s, 3 H, COCH_3), 1.62-1.72 (m, 2 H, CH_2), 1.24-1.38 (m, 8 H, CH_2), 0.84-0.87 (t, 3 H, CH_3); FAB-MS 299 (MH^+ , 40), 257 (100), 79 (24) (Figure 2J).

16
EXAMPLE 5

Synthesis of 2-(Methoxymethyleneoxy)thioanisole (15)(Method A)

To a reaction mixture containing 2-hydroxythioanisole (1, 1 g, 7.14 mmol) in dry pyridine (0.3 g, 3.9 mmol) was added powdered KOH (0.4 g, 7.09 mmol) (Figure 2D). The resulting solution was treated with methoxymethylchloride (0.72 g, 9.0 mmol), heated to reflux for 3.5 hours, cooled and partitioned between 1 M NaOH and diethyl ether. The organic solution was washed with 1 M HCl (2 x 30 mL), brine (50 mL), and then dried (MgSO₄). The solvent was removed under vacuo and the crude product was chromatographed on silica gel and eluted with petroleum ether:EtOAc (95:5) to afford the desired product as an colorless oil (1 g, 83%). ¹H NMR (CDCl₃) δ 7.01-7.17 (m, 4 H, ArH), 5.25 (s, 2 H, CH₂), 3.52 (s, 3 H, OCH₃), 2.43 (s, 3 H, SCH₃); FAB-MS 184 (MH⁺ -1, 20), 167 (25), 149 (100) (Figure 2D).

EXAMPLE 6

Synthesis of 2-(Methoxymethyleneoxy)thioanisole (15)(Method B)

To a reaction mixture containing 2-hydroxythioanisole (1, 1 g, 7.14 mmol) in dry acetonitrile (30 mL) was added potassium fluoride activated alumina powder (8 g) and methoxymethylchloride (0.72 g, 9.0 mmol). The mixture was stirred overnight at room temperature. The reaction mixture was filtered over celite and the solvent was evaporated under vacuo. The residue was partitioned between water and diethyl ether. The organic solution was washed with water and then dried (MgSO₄). The solvent was removed under vacuo and the crude product was chromatographed on silica gel and eluted with petroleum ether:EtOAc (95:5) to afford the desired product as an colorless oil (1.1 g, 85%).

EXAMPLE 7

35

Synthesis of 3-Methylmercapto-2-(methoxy)methyleneoxy-1-methyl benzoate (16)

To 2-(methoxy)methyleneoxy-1-thioanisole (15, 1.06 g, 5.7 mmol) in 30 mL of freshly distilled THF cooled in an ice bath

was added n-BuLi (2.6 mL of 2.5 M solution in hexane, 6.27 mmol) and the reaction mixture was stirred at room temperature for 1 hour (Figure 2D). The bright yellow solution was cooled to -78°C and methylchloroformate (1.1 g, 11.7 mmol, 0.92 mL) was added
5 all at once, and the mixture was then stirred at room temperature for 14 hours. The reaction mixture was quenched by the addition of saturated NH₄Cl and the solution was concentrated under vacuo. The residue was diluted with water (50 mL) and extracted with CH₂Cl₂ (3 x 30 mL). The combined organic solution was washed
10 with brine, water, and then dried (MgSO₄). The solvent was removed under reduced pressure and the residue was chromatographed on silica gel and eluted with petroleum ether/EtOAc 96:4 (starting material was recovered at this polarity) and then 90:10 to afford the desired product **16** as a oil (0.61 g, 44%).
15 ¹H NMR δ 7.55-7.58 (dd, 1 H, ArH), 7.28-7.31 (dd, 1 H, ArH), 7.13-7.18 (t, 1 H, ArH), 5.1 (s, 2 H, CH₂), 3.90 (s, 3 H, COOCH₃), 3.63 (s, 3 H, OCH₃), 2.44 (s, 3 H, SCH₃); FAB-MS 243 (MH⁺ - 1, 30), 211 (100).

20

EXAMPLE 8

Synthesis of 3-(Methylmercapto)methylsalicylate (17)

A reaction mixture comprising of **16** (0.6 g, 2.47 mmol) in THF (0.23 mL), water (2 mL), and 6 M HCl (5 mL) was heated at 60°C for 6 hours (Figure 2D). The reaction mixture was
25 poured into a equal volume of saturated NaCl and the aqueous solution was extracted with diethyl ether (3 x 20 mL). The combined organic solution was dried (MgSO₄), filtered and the solvent removed under vacuo. The crude product was chromatographed on silica gel and eluted with petroleum
30 ether:EtOAc (95:5) to afford **17** as a crystalline white solid (0.3 g, 61%). ¹H NMR (CDCl₃) δ 11.38 (s, 1 H, OH), 7.65-7.69 (dd, 1 H, ArH), 7.35-7.38 (dd, 1 H, ArH), 6.86-6.91 (t, 1 H, ArH), 3.96 (s, 3 H, OCH₃), 2.46 (s, 3 H, SCH₃); FAB-MS 199 (MH⁺, 70), 198 (M⁺ 95), 167 (100).

35

EXAMPLE 9

Synthesis of 3-(Methylmercapto)salicylic acid (18)

A reaction mixture containing the methylsalicylate derivative **17** (50 mg, 0.25 mmol), powdered KOH (56 mg, 1

mmol) in EtOH:H₂O (3.64 mL:0.36 mL) was heated under reflux for 3.5 hours (Figure 2D). The resultant solution was cooled and acidified with 1 M HCl. The aqueous solution was extracted with EtOAc (3 x 10 mL). The combined organic solution was washed with brine, water, and then dried (MgSO₄). The solvent was removed under reduced pressure to afford the essentially pure salicylic acid derivative **18** as a white solid (38 mg, 82%). ¹H NMR (DMSO-d₆) δ 7.57-7.60 (d, 1H, ArH), 7.39-7.41 (d, 1 H, ArH), 6.92-6.97 (t, 1 H, ArH), 2.41 (s, 3 H, SCH₃); FAB-MS 185 (MH⁺, 20), 184 (MH⁺ -1, 20), 167 (75), 102 (70), 79 (100).

EXAMPLE 10

Synthesis of 3-(Methylmercapto)acetylsalicylic acid (19)

To solution of **18** (46 mg, 0.25 mmol) in 1 mL of CH₂Cl₂ was added dry pyridine (20 mg, 50 μL, 0.3 mmol) at 0°C (Figure 2D). The solution was stirred at 0°C for 10 minutes followed by the addition of acetyl chloride (~30 μL, 0.4 mmol). The reaction mixture was stirred overnight at 0°C and then the solvent was removed under vacuo. The residue was partitioned between water and EtOAc. The organic solution was washed with 1 M HCl (10 mL), water (50 mL), and then dried (MgSO₄). The solvent was evaporated to afford a oil which was chromatographed on silica gel and eluted with hexanes:EtOAc (initially 70:30, then 50:50) to afford the desired product as a white solid (11 mg, 20% yield). ¹H NMR (CDCl₃) δ 7.86-7.89 (d, 1 H, ArH), 7.46-7.44 (d, 1 H, ArH), 7.32-7.36 (t, 1 H, ArH), 2.45 (s, 3 H, SCH₃), 2.38 (s, 3 H, CH₃); FAB-MS 227 (MH⁺, 15) 226 (MH⁺ -1, 10), 167 (50), 157 (30), 102 (100).

EXAMPLE 11

Synthesis of 2-Fluoro-1-methoxymethylphenol (21)

To a reaction mixture containing 2-fluorophenol (**20**, 2 g, 17.84 mmol) in 30 mL of dry pyridine was added powdered KOH (1 g, 17.71 mmol) and methoxymethyl chloride (1.8 g, 22.49 mmol) and this reaction mixture was heated under reflux for 3.5 hours (Figure 2E). The reaction was cooled and partitioned between 1 M NaOH and ethyl ether (2 x 30 mL). The organic solution was washed with 1 M HCl (2 x 20 mL), water, and then

dried (MgSO_4), filtered, and the solvent removed under vacuo to afford a oily residue. The crude product was purified by column chromatography (EtOAc :hexanes; 5:95) to afford the desired product as a pale yellow oil in 62% yield. ^1H NMR (CDCl_3) δ 6.95-7.22 (m, 4 H, ArH), 5.21 (s, 2 H, CH_2), 3.52 (s, 3 H, CH_3).

EXAMPLE 12

Synthesis of 3-Fluoro-2-methoxymethyleneoxyphenylmethyl sulfide (22)

A flame-dried 3-necked flask was charged with 2-fluoro-1-methoxymethylphenol (21, 1.07 g, 6.4 mmol) in 30 mL of freshly distilled THF under argon and this mixture was cooled to -78°C (Figure 2E). $n\text{BuLi}$ (2.5 M solution in hexane, 3 mL, 7.25 mmol) was added to this reaction mixture which was allowed to stir at -78°C for 2.5 hours under argon. Methyldisulfide (0.68 g, 7.25 mmol) was then added to the mixture at -78°C and then the acetone/dry ice bath was removed and the reaction was allowed to proceed at room temperature for 20 hours. Sat. NH_4Cl (~ 20 mL) was added to the mixture which was then stirred for an additional 10 min and then extracted with ethyl ether (3 x 10 mL). The combined organic solution was washed with brine, water and then dried (MgSO_4) and filtered. The solvent was removed under vacuo to afford the crude product which was purified by flash chromatography on silica gel (EtOAc :hexanes; 5:95) to yield a yellow oil (0.8 g, 79%). ^1H NMR (CDCl_3) δ 7.0-7.04 (m, 1 H, ArH), 6.89-6.92 (m, 2 H, ArH), 5.18 (s, 2 H, CH_2), 3.64 (s, 3 H, CH_3), 2.44 (s, 3 H, CH_3).

EXAMPLE 13

Synthesis of 3-Fluoro-2-hydroxyphenylmethyl sulfide (23)

A reaction mixture containing the MOM-protected phenol (22, 0.57 g, 2.8 mmol) and 6 M HCl (~ 5 mL) in 10% $\text{THF-H}_2\text{O}$ (2 mL) was heated at 60°C for 5 hours (Figure 2E). Sat. NaCl was added to the reaction mixture and the aqueous solution was extracted with ethyl ether (3 x 10 mL). The combined organic solution was washed with water, dried (MgSO_4), filtered and the solvent removed under vacuo to afford a oily residue. The product was purified by flash chromatography (5% EtOAc :hexanes) to yield a pale yellow oil (190 mg, 46%). ^1H NMR (CDCl_3) δ 7.17-

7.21 (dd, 1 H, ArH), 7.0-7.06 (m, 1 H, ArH), 6.79-6.86 (m, 1 H, ArH), 6.23-6.24 (d, 1 H, OH), 2.38 (s, 3 H, CH₃).

EXAMPLE 14

5 Synthesis of 2-Acetoxy-3-fluorophenylmethyl sulfide (24)

To a solution containing the phenol derivative (23, 140 mg, 0.9 mmol) in CH₂Cl₂ (2 mL) was added dry pyridine (74 mg, 0.92 mmol) and acetic anhydride (74 mg, 0.92 mmol) and the reaction mixture was allowed to stir overnight at room
10 temperature (Figure 2E). The solvent was removed under reduced pressure and diluted with water. The aqueous solution was extracted with ethyl ether (2 x 10 mL) and the ethereal extracts were dried (MgSO₄), filtered, and the solvent evaporated. Column chromatography (10% EtOAc:hexanes) of the crude product gave
15 the pure acetoxy derivative as a colorless oil (104 mg, 60%). ¹H NMR (CDCl₃) δ 7.14-7.18 (m, 1 H, ArH), 6.96-7.02 (m, 2 H, ArH), 2.44 (s, 3 H, CH₃), 2.37 (s, 3 H, COCH₃).

EXAMPLE 15

20 Synthesis of 2,4-difluoro-1-methoxymethylphenol (26)

To a reaction mixture containing 2,4-difluorophenol (25, 2 g, 15.37 mmol) in 30 mL of dry pyridine was added powdered KOH (0.854 g, 15.25 mmol) and methoxymethyl chloride (1.6 g, 19.37 mmol) and this reaction mixture was heated under
25 reflux for 3.5 hours (Figure 2F). The reaction was cooled and partitioned between 1 M NaOH and ethyl ether (2 x 30 mL). The organic solution was washed with 1 M HCl (2 x 20 mL), water, and then dried (MgSO₄), filtered, and the solvent removed under vacuo to afford a oily residue. The crude product was purified by
30 column chromatography (EtOAc:hexanes; 5:95) to afford the desired product as a pale yellow oil in 71% yield. ¹H NMR (CDCl₃) δ 7.1-7.16 (m, 1 H, ArH), 6.78-6.88 (m, 2 H, ArH), 5.15 (s, 2 H, CH₂), 3.52 (s, 3 H, CH₃).

35

EXAMPLE 16

Synthesis of 2,4-Difluoro-3-trimethylsilyl-1-methoxymethylphenol (27)

A flame-dried 3-necked flask was charged with 2,4-difluoro-1-methoxymethylphenol (26, 0.84 g, 4.8 mmol) in 30 mL

of freshly distilled THF under argon and this mixture was cooled to -78°C (Figure 2F). nBuLi (2.5 M solution in hexane, 2.2 mL, 5.43 mmol) was added to this reaction mixture which was allowed to stir at -78°C for 2.5 hours under argon. Chlorotrimethyl silane (1.0 M solution in THF, 5.43 mL, 5.43 mmol) was then added to the deep pink colored mixture at -78°C and then the acetone/dry ice bath was removed and the reaction was allowed to proceed at room temperature for 14 h. Sat. NH₄Cl (~20 mL) was added to the mixture which was then stirred for an additional 10 minutes and then extracted with ethyl ether (3 x 10 mL). The combined organic solution was washed with brine, water and then dried (MgSO₄) and filtered. The solvent was removed under vacuo to afford the crude product which was purified by flash chromatography on silica gel (EtOAc:hexanes; 5:95) to yield a yellow oil (0.8 g, 79%). ¹H NMR (CDCl₃) δ 7.09-7.17 (m, 1 H, ArH), 6.68-6.74 (m, 1 H, ArH), 5.13 (s, 2 H, CH₂), 3.52 (s, 3 H, CH₃), 0.36-0.37 (t, 9 H, Si(CH₃)₃); FAB-MS 247 (MH⁺, 70), 229 (40), 219 (60), 189 (58), 157 (40), 133 (60), 79 (100).

20

EXAMPLE 17

Synthesis of 2,4-Difluoro-6-methylmercapto-3-trimethylsilyl-1-methoxymethyl phenol (28)

A flame-dried 3-necked flask was charged with 2,4-difluoro-3-trimethylsilyl-1-methoxymethylphenol (27, 0.63 g, 2.56 mmol) in 15 mL of freshly distilled THF under argon and this mixture was cooled to -78°C (Figure 2F). nBuLi (2.5 M solution in hexane, 1.16 mL, 2.9 mmol) was added to this reaction mixture which was allowed to stir at -78°C for 2.5 h under argon. Methyl disulfide (0.27 g, 2.9 mmol) was then added to the mixture at -78°C and then the acetone/dry ice bath was removed and the reaction was allowed to proceed at room temperature for 14 hours. Sat. NH₄Cl (~ 10 mL) was added to the mixture which was then stirred for an additional 10 min and then extracted with ethyl ether (3 x 10 mL). The combined organic solution was washed with brine, water and then dried (MgSO₄) and filtered. The solvent was removed under vacuo to afford the crude product which was purified by flash chromatography on silica gel (EtOAc:hexanes; 5:95) to yield a yellow oil (0.51 g, 68%). ¹H NMR

(CDCl₃) δ 6.55-6.58 (dd, 1 H, ArH), 5.09 (s, 2 H, CH₂), 3.63 (s, 3 H, CH₃), 2.41 (s, 3 H, CH₃), 0.34-0.35 (t, 9 H, Si(CH₃)₃); FAB-MS 293 (MH⁺, 24), 292 (M⁺, 70), 262 (66), 261 (100).

5

EXAMPLE 18

Synthesis of 2,4-Difluoro-6-methylmercapto-1-methoxy methyl phenol (29)

A reaction mixture containing the trimethylsilyl derivative (28, 0.51 g, 1.74 mmol) in 10 mL of freshly distilled THF was treated with trifluoroethanol (0.18 g, 1.82 mmol) and tetrabutylammonium fluoride (1 M solution in THF, 1.74 mL, 1.74 mmol) at -78°C under argon (Figure 2F). The reaction mixture was allowed to stir at -78°C for 20 min and at room temperature for 30 minutes. The reaction was quenched by the addition of water, followed by extraction with ethyl ether (2 x 15 mL). The combined organic extracts were washed with water, dried (MgSO₄), filtered, and the solvent removed under vacuo. Silica gel chromatography (5% EtOAc:hexanes) gave the pure product as a colorless oil (270 mg, 71%). ¹H NMR (CDCl₃) δ 6.6-6.64 (m, 2 H, ArH), 5.11 (s, 2 H, CH₂), 3.63 (s, 3 H, CH₃), 2.42 (s, 3 H, CH₃).

EXAMPLE 19

Synthesis of 3,5-Difluoro-2-hydroxyphenylmethyl sulfide (30)

A reaction mixture containing the MOM-protected phenol (29, 270 mg, 1.22 mmol) and 6 M HCl (~1 mL) in 10% THF-H₂O (1 mL) was heated at 60°C for 4 hours (Figure 2F). Sat. NaCl was added to the reaction mixture and the aqueous solution was extracted with ethyl ether (3 x 10 mL). The combined organic solution was washed with water, dried (MgSO₄), filtered and the solvent removed under vacuo to afford a oily residue. The product was purified by flash chromatography (5% EtOAc:hexanes) to yield a pale yellow oil (110 mg, 53%). ¹H NMR (CDCl₃) δ 6.87-6.91 (m, 1 H, ArH), 6.75-6.82 (m, 1 H, ArH), 5.85 (d, 1 H, OH), 2.41 (s, 3 H, CH₃).

35

EXAMPLE 20

Synthesis of 2-Acetoxy-3,5-difluorophenylmethyl sulfide (31)

A reaction mixture consisting of the phenol derivative (30, 110 mg, 0.62 mmol), dry pyridine (58 mg, 0.64 mmol) and

acetic anhydride (63 mg, 0.63 mmol), in CH_2Cl_2 (2 mL) was allowed to stir overnight at room temperature (Figure 2F). The solvent was removed under reduced pressure and diluted with water. The aqueous solution was extracted with ethyl ether (2 x 10 mL) and the ethereal extracts were dried (MgSO_4), filtered, and the solvent evaporated. Column chromatography (5% EtOAc:hexanes) of the crude product gave the pure acetoxy derivative as a colorless oil (75 mg, 56%). ^1H NMR (CDCl_3) δ 6.67-6.73 (m, 2 H, ArH), 2.43 (s, 3 H, CH_3), 2.36 (s, 3 H, COCH_3); FAB-MS 219 (MH^+ , 28), 218 (M^+ , 30), 176 (84), 157 (70), 149 (42), 121 (46), 79 (100).

EXAMPLE 21

Synthesis of the 2-Hydroxyphenylalkyl Sulfides

A reaction mixture containing 2-hydroxythiophenol (32, 3.96 mmol) in 4 mL of dry DMF was treated with KHCO_3 (4.52 mmol) and alkyl halide (3.96 mmol) and allowed to stir at room temperature overnight (Figure 2G). The reaction mixture was diluted with water and extracted with ethyl ether (3 x 20 mL). The combined organic extracts were washed with water (2 x 50 mL), dried (MgSO_4), filtered, and the solvent removed under vacuo. The residue was chromatographed on silica gel and eluted with EtOAc:hexanes (3:97) to afford the desired products.

2-Hydroxyphenylethyl sulfide (33) colorless oil in 60% yield. ^1H NMR (CDCl_3) δ 7.44-7.48 (dd, 1 H, ArH), 7.23-7.28 (m, 1 H, ArH), 6.9-7.0 (dd, 1 H, ArH), 6.84-6.89 (m, 1 H, ArH), 6.7 (s, 1 H, OH), 2.67-2.75 (q, 2 H, CH_2), 1.19-1.24 (t, 3 H, CH_3).

2-Hydroxyphenylpropyl sulfide (34) colorless oil in 77% yield. ^1H NMR (CDCl_3) δ 7.44-7.47 (dd, 1 H, ArH), 7.22-7.26 (m, 1 H, ArH), 6.96-6.99 (dd, 1 H, ArH), 6.83-6.89 (t, 1 H, ArH), 6.76 (s, 1 H, OH), 2.64-2.69 (t, 2 H, CH_2), 1.55-1.61 (m, 2 H, CH_2), 0.95-1.0 (t, 3 H, CH_3); FAB-MS MH^+ 169 (25), M^+ 168 (60), 93 (22), 79 (100).

2-Hydroxyphenyl-2-methylpropyl sulfide (35) colorless oil in 78% yield. ^1H NMR (CDCl_3) δ 7.44-7.47 (dd, 1 H, ArH), 7.21-7.25 (m, 1 H, ArH), 6.96-6.99 (dd, 1 H, ArH), 6.83-6.88 (t, 1 H, ArH), 6.74 (s, 1 H, OH), 2.58-2.60 (dd, 2 H, CH_2), 1.71-1.78 (m, 1 H, CH), 0.99-1.01 (d, 6 H, CH_3).

5 2-Hydroxyphenylpentyl sulfide (36) colorless oil in 89% yield. ^1H NMR (CDCl_3) δ 7.44-7.47 (dd, 1 H, ArH), 7.22-7.28 (m, 1 H, ArH), 6.96-6.99 (dd, 1 H, ArH), 6.83-6.89 (t, 1 H, ArH), 6.75 (s, 1 H, OH), 2.65-2.70 (t, 2 H, CH_2), 1.5-1.58 (m, 2 H, CH_2), 1.25-1.37 (m, 4 H, CH_2), 0.84-0.91 (t, 3 H, CH_3).

10 2-Hydroxyphenylhexyl sulfide (37) colorless oil in 84% yield. ^1H NMR (CDCl_3) δ 7.44-7.47 (dd, 1 H, ArH), 7.22-7.28 (m, 1 H, ArH), 6.96-6.99 (dd, 1 H, ArH), 6.83-6.89 (t, 1 H, ArH), 6.75 (s, 1 H, OH), 2.65-2.70 (t, 2 H, CH_2), 1.5-1.59 (m, 2 H, CH_2), 1.22-1.41 (complex multiplet, 6 H, CH_2), 0.84-0.89 (t, 3 H, CH_3).

15 2-Hydroxyphenylheptyl sulfide (38) colorless oil in 67% yield. ^1H NMR (CDCl_3) δ 7.44-7.47 (dd, 1 H, ArH), 7.22-7.28 (m, 1 H, ArH), 6.96-6.99 (dd, 1 H, ArH), 6.83-6.89 (m, 1 H, ArH), 6.75 (s, 1 H, OH), 2.65-2.70 (t, 2 H, CH_2), 1.5-1.59 (m, 2 H, CH_2), 1.25-1.35 (complex multiplet, 8 H, CH_2), 0.84-0.88 (t, 3 H, CH_3).

20 2-Hydroxyphenyloctyl sulfide (39) colorless oil in 77% yield. ^1H NMR (CDCl_3) δ 7.44-7.47 (dd, 1 H, ArH), 7.22-7.28 (m, 1 H, ArH), 6.96-6.99 (dd, 1 H, ArH), 6.83-6.89 (m, 1 H, ArH), 6.75 (s, 1 H, OH), 2.65-2.70 (t, 2 H, CH_2), 1.5-1.59 (m, 2 H, CH_2), 1.24-1.38 (complex multiplet, 10 H, CH_2), 0.84-0.88 (t, 3 H, CH_3).

25 2-Hydroxyphenylnonyl sulfide (40) colorless oil in 69% yield. ^1H NMR (CDCl_3) δ 7.44-7.47 (dd, 1 H, ArH), 7.23-7.26 (m, 1 H, ArH), 6.97-6.99 (dd, 1 H, ArH), 6.84-6.88 (m, 1 H, ArH), 6.75 (s, 1 H, OH), 2.66-2.70 (t, 2 H, CH_2), 1.54-1.56 (m, 2 H, CH_2), 1.33-1.37 (m, 2 H, CH_2), 1.24-1.28 (complex multiplet, 10 H, CH_2), 0.85-0.89 (t, 3 H, CH_3).

30 2-Hydroxyphenylcyclohexyl sulfide (41) colorless oil in 66% yield. ^1H NMR (CDCl_3) δ 7.42-7.48 (dd, 1 H, ArH), 7.24-7.29 (m, 1 H, ArH), 6.97-7.03 (dd, 1 H, ArH), 6.8-7.0 (m, 2 H, ArH & OH), 2.75-2.85 (m, 1 H, CH), 1.90-1.94 (m, 2 H, CH_2), 1.74-1.77 (m, 2 H, CH_2), 1.15-1.68 (m, 6 H, CH_2).

35 2-Hydroxyphenylcycloheptyl sulfide (42) colorless oil in 66% yield. ^1H NMR (CDCl_3) δ 7.43-7.45 (dd, 1 H, ArH), 7.24-7.29 (m, 1 H, ArH), 6.97-7.0 (dd, 1 H, ArH), 6.83-6.88 (m, 3 H, ArH & OH), 2.97-3.05 (m, 1 H, CH), 1.40-2.27 (m, 12 H, CH_2).

2-Hydroxyphenylbenzyl sulfide (43) white solid in 66% yield. ^1H NMR (CDCl_3) δ 7.21-7.27 (m, 5 H, ArH), 7.06-7.09 (m, 2 H, ArH), 6.90-6.93 (dd, 1 H, ArH), 6.77-6.82 (m, 1 H, ArH), 6.52 (s, 1 H, OH), 3.84 (s, 2 H, CH_2).

2-Hydroxyphenyl-2-phenethyl sulfide (44): colorless oil in 78% yield. ^1H NMR (CDCl_3) δ 7.46-7.49 (dd, 1 H, ArH), 7.27-7.30 (m, 3 H, ArH), 7.13-7.15 (d, 2 H, ArH), 6.98-7.01 (d, 1 H, ArH), 6.88-6.90 (t, 1 H, ArH), 6.64 (s, 1 H, OH), 2.94-2.98 (m, 2 H, CH_2), 2.82-2.86 (t, 2 H, CH_2).

2-Hydroxyphenyl-3-phenylpropyl sulfide (45): colorless oil in 79% yield. ^1H NMR (CDCl_3) δ 7.43-7.46 (dd, 1 H, ArH), 7.12-7.29 (m, 6 H, ArH), 6.97-6.99 (dd, 1 H, ArH), 6.83-6.88 (m, 1 H, ArH), 6.72 (s, 1 H, OH), 2.67-2.72 (m, 4 H, CH_2), 1.82-1.92 (m, 2 H, CH_2).

2-Hydroxyphenyl-3-phenoxypropyl sulfide (46): colorless oil in 72% yield. ^1H NMR (CDCl_3) δ 7.46-7.48 (dd, 1 H, ArH), 7.24-7.29 (m, 3 H, ArH), 6.84-6.98 (m, 5 H, ArH), 4.01-4.05 (t, 2 H, CH_2), 2.88-2.92 (t, 2 H, CH_2), 1.99-2.06 (m, 2 H, CH_2).

2-Hydroxyphenyl-8-(methoxycarbonyl)heptyl sulfide (47): colorless oil in 53% yield. ^1H NMR (CDCl_3) δ 7.43-7.46 (dd, 1 H, ArH), 7.23-7.28 (m, 1 H, ArH), 6.96-6.99 (dd, 1 H, ArH), 6.86-6.87 (m, 1 H, ArH), 6.74 (s, 1 H, ArOH), 3.66 (s, 3 H, CH_3), 2.65-2.70 (t, 2 H, CH_2), 2.26-2.31 (t, 2 H, CH_2), 1.52-1.62 (m, 4 H, CH_2), 1.26-1.39 (m, 6 H, CH_2); FAB-MS 283 (MH^+ , 30), 282 (M^+ , 100), 251 (40), 139 (34), 79 (50).

EXAMPLE 23

25 Synthesis of 2-Hydroxyphenyl-8-(carboxy)heptyl sulfide (48)

To a reaction flask containing (47, 0.5 g, 1.77 mmol) in a $\text{EtOH}:\text{H}_2\text{O}$ (36mL:4mL) mixture was added powdered KOH (0.4 g, 7.08 mmol) and this reaction was heated under reflux for 3.5 hours. The solvent was removed under vacuo and the residue was diluted with 1 M HCl (pH ~2). The aqueous mixture was extracted with EtOAc (3 x 20 mL). The combined organic solution was washed with brine, water, and then dried (MgSO_4). The solvent was removed under reduced pressure to afford essentially pure carboxylic acid as an oil (89%). ^1H NMR (CDCl_3) δ 7.43-7.46 (dd, 1 H, ArH), 7.22-7.28 (m, 1 H, ArH), 6.96-6.99 (dd, 1 H, ArH), 6.84-6.89 (m, 1 H, ArH), 6.74 (s, 1 H, ArOH), 2.65-2.70 (t, 2 H, CH_2), 2.31-2.36 (t, 2 H, CH_2), 1.5-1.66 (m, 4 H, CH_2), 1.19-1.41 (m, 6 H, CH_2).

EXAMPLE 24Synthesis of 2-Hydroxyphenyl-2-butoxyethyl sulfide (66)

To a flame-dried flask containing 2-butoxyethanol (64, 0.5 g, 4.23 mmol) in 10 mL of dry THF was added triphenylphosphine (2.66 g, 10.15 mmol), dry pyridine (0.39 g, 4.9 mmol) and carbon tetrabromide (1.4 g, 4.23 mmol) (Figure 2H). After stirring for 1 hour at room temperature, the reaction mixture was treated with hexanes and the precipitate was filtered. The filtrate was concentrated under reduced pressure and the residue was treated with 1 M HCl. The aqueous solution was extracted with hexanes (3 x 10 mL). The combined organic solution was washed with water, dried (MgSO₄), filtered, and the solvent evaporated under vacuo to afford a oil. ¹H NMR analysis revealed the oil to be a mixture of starting alcohol 64 and the desired 2-butoxyethyl bromide (65) and was used in the subsequent reaction without further purification. To a reaction mixture containing 2-hydroxythiophenol (32, 100 mg, 0.8 mmol) in 1 mL of dry DMF was added KHCO₃ (95 mg, 0.95 mmol) and the crude 2-butoxyethyl bromide and this reaction mixture was stirred overnight at room temperature. The reaction was diluted with water and extracted with ethyl ether (2 x 10 mL). The organic solution was washed with water, dried (MgSO₄), filtered, and the solvent evaporated under vacuo to afford a oil. The crude phenol was chromatographed on silica gel (EtOAc:hexanes; 2:98) to afford the desired phenol 66 (34% yield based on starting 2-hydroxythiophenol). ¹H NMR (CDCl₃) δ 7.46-7.49 (dd, 1 H, ArH), 7.24-7.29 (m, 1 H, ArH), 7.41 (s, 1 H, OH), 6.96-6.99 (dd, 1 H, ArH), 6.81-6.87 (m, 1 H, ArH), 3.45-3.5 (m, 4 H, CH₂), 2.86-2.90 (t, 2 H, CH₂), 1.52-1.63 (m, 2 H, CH₂), 1.33-1.45 (m, 2 H, CH₂), 0.88-0.96 (t, 3 H, CH₃).

2-Hydroxyphenyl-3-ethoxypropyl sulfide (70): was prepared in a similar manner as described above in 67% yield (Figure 2H). ¹H NMR (CDCl₃) δ 7.45-7.47 (dd, 1 H, ArH), 7.23-7.28 (dd, 1 H, ArH), 6.97-6.99 (dd, 1 H, ArH), 6.84-6.89 (s and d of t, 2 H, OH & ArH), 3.43-3.51 (m, 4 H, CH₂), 2.77-2.81 (t, 2 H, CH₂), 1.77-1.84 (m, 2 H, CH₂), 1.17-1.20 (t, 3 H, CH₃).

2-Hydroxyphenyl-trans-hept-2-enyl sulfide (74): was prepared in a similar manner as described above in 54% yield

(Figure 2I). ^1H NMR (CDCl_3) δ 7.39-7.42 (dd, 1 H, ArH), 7.22-7.27 (m, 1 H, ArH), 6.95-6.97 (dd, 1 H, ArH), 6.82-6.87 (d of t, 1 H, ArH), 6.7 (s, 1 H, OH), 5.36-5.46 (m, 1 H, olefinic H), 5.19-5.29 (m, 1 H, olefinic H), 3.46-3.49 (d, 2 H, CH_2), 1.66-1.93 (m, 2 H, CH_2),
5 1.18-1.39 (m, 4 H, CH_2), 0.82-0.94 (t, 3 H, CH_3).

2-Hydroxyphenyl-hept-2-ynyl sulfide (82): was prepared in a similar manner as described above in 92% yield (Figure 2I). ^1H NMR (CDCl_3) δ 7.51-7.54 (dd, 1 H, ArH), 7.27-7.31 (t, 1 H, ArH), 6.98-7.01 (dd, 1 H, ArH), 6.86-6.9 (d of t, 1 H, ArH), 6.78 (s, 1 H, OH),
10 3.39-3.4 (t, 2 H, CH_2), 2.11-2.16 (m, 2 H, CH_2), 1.26-1.46 (m, 4 H, CH_2), 0.86-0.97 (t, 3 H, CH_3).

2-Hydroxyphenylhex-2-ynyl sulfide (83) was prepared in a similar manner as described above in 51% yield. ^1H NMR (CDCl_3) δ 7.51-7.54 (dd, 1 H, ArH), 7.26-7.32 (t, 1 H, ArH), 6.98-7.01 (dd, 1 H, ArH), 6.85-6.9 (t, 1 H, ArH), 6.78 (s, 1 H, OH), 3.39-3.41 (t, 2 H, CH_2), 2.08-2.15 (m, 2 H, CH_2), 1.43-1.55 (m, 2 H, CH_2), 0.89-0.95 (t, 3 H, CH_3).

2-Hydroxyphenylpent-2-ynyl sulfide (84) was prepared in a similar manner as described above in 59% yield. ^1H NMR (CDCl_3) δ 7.51-7.54 (dd, 1 H, ArH), 7.26-7.32 (t, 1 H, ArH), 6.98-7.01 (dd, 1 H, ArH), 6.85-6.9 (t, 1 H, ArH), 6.78 (s, 1 H, OH), 3.39-3.41 (t, 2 H, CH_2), 2.08-2.15 (m, 2 H, CH_2), 0.89-0.95 (t, 3 H, CH_3).

2-Hydroxyphenylbut-2-ynyl sulfide (85) was prepared in a similar manner as described above in 61% yield. ^1H NMR (CDCl_3) δ 7.51-7.54 (dd, 1 H, ArH), 7.27-7.32 (t, 1 H, ArH), 6.98-7.01 (dd, 1 H, ArH), 6.86-6.91 (t, 1 H, ArH), 6.78 (s, 1 H, OH), 3.35-3.38 (q, 2 H, CH_2), 1.77-1.79 (t, 3 H, CH_3).

2-Hydroxyphenyl-prop-2-ynyl sulfide (86): was prepared in a similar manner as described above in 58% yield (Figure 2G). ^1H NMR (CDCl_3) δ 7.54-7.57 (dd, 1 H, ArH), 7.29-7.34 (t, 1 H, ArH), 7.0-7.02 (dd, 1 H, ArH), 6.87-6.92 (t, 1 H, ArH), 6.72 (s, 1 H, OH), 3.39-3.4 (d, 2 H, CH_2), 2.25 (s, 1 H, CH).

2-Hydroxythiophenoxy)methylpropionate (95): colorless oil in 67% yield (Figure 2K). ^1H NMR (CDCl_3) δ 7.42-7.45 (dd, 1 H, ArH), 7.25-7.3 (m, 1 H, ArH), 7.06 (s, 1 H, OH), 6.9-7.0 (dd, 1 H, ArH), 6.86-6.89 (m, 1 H, ArH), 3.61-3.67 (s and q, 4 H, CH_3 and CH), 1.45-1.47 (d, 3 H, CH_3); FAB-MS 213 (MH^+ , 36), 212 (M^+ , 90), 181 (30), 153 (100), 79 (100).

2-(2-Hydroxythiophenoxy)propionic acid (96): obtained in a similar manner as a colorless oil in 77% yield (Figure 2K). ¹H NMR (CDCl₃) δ 7.46-7.49 (dd, 1 H, ArH), 7.29-7.34 (m, 1 H, ArH), 6.9-7.01 (dd, 1 H, ArH), 6.85-6.89 (m, 1 H, ArH), 3.59-3.66 (q, 4 H, CH), 1.47-1.50 (d, 3 H, CH₃); FAB-MS 199 (MH⁺, 20), 198 (M⁺, 52), 185 (60), 153 (60), 137 (50), 93 (82), 79 (100).

EXAMPLE 25

10 Procedure For the Acetylation of 2-Hydroxyphenylalkyl sulfides

A reaction mixture containing appropriate arenol (2.8 mmol) in 1 mL of CH₂Cl₂ was treated with dry pyridine (2.85 mmol) and acetic anhydride (2.85 mmol) and this reaction mixture was allowed to stir at room temperature overnight. The solvent was removed under vacuo and diluted with water. The aqueous solution was extracted with ethyl ether (2 x 10 mL) and the combined ether extracts were washed with water, dried (MgSO₄), filtered, and the solvent removed under reduced pressure. The crude product was purified by column chromatography on silica gel (EtOAc:hexanes; 5:95).

2-Acetoxyphenylethyl sulfide (49) was obtained in 74% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.35-7.38 (m, 1 H, ArH), 7.19-7.22 (m, 2 H, ArH), 7.03-7.06 (m, 1 H, ArH), 2.86-2.93 (q, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.27-1.32 (t, 3 H, CH₃); FAB-MS 197 (MH⁺, 65), 196 (M⁺, 80), 154 (100), 79 (35), 57 (50).

2-Acetoxyphenylpropyl sulfide (50) was obtained in 68% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.36-7.39 (m, 1 H, ArH), 7.19-7.20 (m, 2 H, ArH), 7.03-7.06 (m, 1 H, ArH), 2.82-2.87 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.61-1.69 (q, 2 H, CH₂), 0.99-1.0 (t, 3 H, CH₃); FAB-MS 211 (MH⁺, 45), 210 (M⁺, 60), 168 (100), 79 (30).

2-Acetoxyphenyl-2-methylpropyl sulfide (51) was obtained in 77% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.35-7.38 (m, 1 H, ArH), 7.18-7.21 (m, 2 H, ArH), 7.02-7.05 (m, 1 H, ArH), 2.74-2.76 (d, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.82-1.86 (m, 1 H, CH), 1.01-1.03 (d, 6 H, CH₃); FAB-MS 225 (MH⁺, 70), 224 (M⁺, 98), 183 (100), 79 (30).

2-Acetoxyphenylpentyl sulfide (52) was obtained in 92% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.35-7.38 (m, 1 H, ArH), 7.19-7.25 (m, 2 H, ArH), 7.02-7.05 (m, 1 H, ArH), 2.83-2.88 (t, 2 H, CH₂),

2.34 (s, 3 H, CH₃), 1.54-1.65 (m, 2 H, CH₂), 1.31-1.42 (m, 4 H, CH₂), 0.86-0.91 (t, 3 H, CH₃); FAB-MS 239 (MH⁺, 65), 238 (M⁺, 90), 197 (100), 196 (82), 79 (35).

5 2-Acetoxyphenylhexyl sulfide (53) was obtained in 82% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.35-7.38 (m, 1 H, ArH), 7.18-7.22 (m, 2 H, ArH), 7.02-7.06 (m, 1 H, ArH), 2.84-2.89 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.60-1.65 (m, 2 H, CH₂), 1.39-1.44 (m, 4 H, CH₂), 1.25-1.29 (m, 4 H, CH₂), 0.86-0.90 (t, 3 H, CH₃); FAB-MS 253 (MH⁺, 44), 252 (M⁺, 55), 211 (100), 210 (80).

10 2-Acetoxyphenylheptyl sulfide (54) was obtained in 67% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.35-7.38 (m, 1 H, ArH), 7.17-7.21 (m, 2 H, ArH), 7.02-7.05 (m, 1 H, ArH), 2.83-2.88 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.57-1.67 (m, 2 H, CH₂), 1.27-1.41 (m, 8 H, CH₂), 0.85-0.90 (t, 3 H, CH₃); FAB-MS 267 (MH⁺, 40), 266 (M⁺, 55), 225
15 (100), 224 (84), 79 (32).

2-Acetoxyphenyloctyl sulfide (55) was obtained in 66% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.35-7.38 (m, 1 H, ArH), 7.19-7.21 (m, 2 H, ArH), 7.02-7.18 (m, 1 H, ArH), 2.83-2.88 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.57-1.65 (m, 2 H, CH₂), 1.38-1.43 (m, 2 H, CH₂),
20 1.26-1.38 (m, 8 H, CH₂), 0.85-0.89 (t, 3 H, CH₃); FAB-MS 281 (MH⁺, 32), 280 (M⁺, 36), 239 (100), 238 (70), 126 (20), 79 (20).

2-Acetoxyphenylnonyl sulfide (56) was obtained in 85% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.35-7.37 (m, 1 H, ArH), 7.19-7.21 (m, 2 H, ArH), 7.03-7.05 (m, 1 H, ArH), 2.84-2.88 (t, 2 H, CH₂),
25 2.34 (s, 3 H, CH₃), 1.58-1.64 (m, 2 H, CH₂), 1.39-1.42 (m, 2 H, CH₂), 1.26-1.29 (m, 10 H, CH₂), 0.86-0.89 (t, 3 H, CH₃); FAB-MS 295 (MH⁺, 28), 294 (M⁺, 40), 253 (100), 252 (80), 126 (25), 79 (32).

2-Acetoxyphenylcyclohexyl sulfide (57) was obtained in 78% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.45-7.47 (dd, 1 H, ArH),
30 7.23-7.27 (dd, 1 H, ArH), 7.17-7.21 (t, 1 H, ArH), 7.04-7.07 (dd, 1 H, ArH), 3.07-3.08 (m, 1 H, CH), 2.34 (s, 3 H, CH₃), 1.94-1.96 (m, 2 H, CH₂), 1.75-1.78 (m, 2 H, CH₂), 1.25-1.62 (m, 6 H, CH₂); FAB-MS 251 (MH⁺, 84), 250 (M⁺, 100), 209 (75), 208 (94), 169 (75), 126 (55), 79 (56).

35 2-Acetoxyphenylcycloheptyl sulfide (58) was obtained in 64% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.41-7.43 (dd, 1 H, ArH), 7.17-7.26 (m, 2 H, ArH), 7.04-7.06 (dd, 1 H, ArH), 3.29-3.34 (m, 1 H, CH), 2.34 (s, 3 H, CH₃), 1.95-2.02 (m, 2 H, CH₂), 1.69-1.72 (m, 2

H, CH₂), 1.46-1.71 (m, 8 H, CH₂); FAB-MS 265 (MH⁺, 55), 264 (M⁺, 94), 222 (80), 169 (100), 126 (52), 95 (72), 79 (80).

5 2-Acetoxyphenylbenzyl sulfide (59) was obtained in 75% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.21-7.32 (m, 7 H, ArH), 7.13-7.16 (m, 1 H, ArH), 7.06-7.07 (m, 1 H, ArH), 4.05 (s, 2 H, CH₂), 2.32 (s, 3 H, CH₃); FAB-MS 259 (MH⁺, 52), 258 (M⁺, 54), 217 (58), 216 (64), 91 (100).

10 2-Acetoxyphenyl-2-phenylethyl sulfide (60) was obtained in 96% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.40-7.43 (dd, 1 H, ArH), 7.18-7.31 (m, 7 H, ArH), 7.05-7.08 (dd, 1 H, ArH), 3.1-3.13 (t, 2 H, CH₂), 2.87-2.91 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃); FAB-MS 273 (MH⁺, 44), 272 (M⁺, 46), 231 (64), 105 (100).

15 2-Acetoxyphenyl-3-phenylpropyl sulfide (61) was obtained in 66% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.15-7.33 (m, 8 H, ArH), 7.03-7.05 (dd, 1 H, ArH), 2.84-2.89 (t, 2 H, CH₂), 2.71-2.76 (t, 2 H, CH₂), 2.33 (s, 3 H, CH₃), 1.91-1.96 (m, 2 H, CH₂); FAB-MS 287 (MH⁺, 36), 286 (M⁺, 40), 245 (100), 244 (70), 117 (50), 91 (90).

20 2-Acetoxyphenyl-3-phenoxypropyl sulfide (62) was obtained in 83% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.41-7.43 (dd, 1 H, ArH), 7.18-7.40 (m, 4 H, ArH), 7.04-7.06 (dd, 1 H, ArH), 6.87-7.03 (m, 3 H, ArH), 4.03-4.07 (t, 2 H, CH₂), 3.06-3.11 (t, 2 H, CH₂), 2.33 (s, 3 H, CH₃), 2.05-2.12 (m, 2 H, CH₂); FAB-MS 303 (MH⁺, 34), 302 (M⁺, 34), 260 (68), 209 (50), 167 (100), 133 (50), 107 (30), 79 (40).

25 2-Acetoxyphenyl-8-carboxyheptyl sulfide (63) was obtained in 47% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.34-7.36 (m, 1 H, ArH), 7.18-7.25 (m, 2 H, ArH), 7.04-7.05 (m, 1 H, ArH), 2.83-2.88 (t, 2 H, CH₂), 2.31-2.36 (s merged with a triplet, 5 H, SCH₃, and CH₂), 1.57-1.64 (m, 4 H, CH₂), 1.31-1.44 (m, 6 H, CH₂); FAB-MS 311 (MH⁺, 28), 293 (22), 268 (70), 251 (100), 126 (44), 79 (70).

30 2-Acetoxyphenyl-2-butoxyethyl sulfide (67) was obtained in 72% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.42-7.45 (m, 1 H, ArH), 7.20-7.24 (m, 2 H, ArH), 7.04-7.19 (m, 1 H, ArH), 3.55-3.60 (t, 2 H, CH₂), 3.40-3.44 (t, 2 H, CH₂), 3.04-3.08 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.49-1.56 (m, 2 H, CH₂), 1.31-1.39 (m, 2 H, CH₂), 0.88-0.93 (t, 3 H, CH₃); FAB-MS 269 (MH⁺, 24), 268 (M⁺, 40), 226 (44), 195 (100), 125 (24).

35 2-Acetoxyphenyl-3-ethoxypropyl sulfide (71) was obtained in 70% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.39-7.41 (m, 1 H,

ArH), 7.19-7.22 (m, 2 H, ArH), 7.03-7.06 (m, 1 H, ArH), 3.43-3.51 (m, 4 H, CH₂), 2.96-2.99 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.86-1.89 (m, 2 H, CH₂), 1.17-1.21 (t, 3 H, CH₃); FAB-MS 255 (MH⁺, 100), 254 (M⁺, 90), 212 (84), 209 (54), 167 (66), 85 (30).

5 2-Acetoxyphenyl-trans-hept-2-enyl sulfide (75) was obtained in 62% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.36-7.39 (m, 2 H, ArH), 7.15-7.25 (dd, 1 H, ArH), 7.03-7.06 (dd, 1 H, ArH), 5.41-5.56 (m, 2 H, olefinic H), 3.45-3.47 (d, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.93-2.0 (m, 2 H, CH₂), 1.2-1.36 (m, 4 H, CH₂), 0.83-0.94 (t, 3 H, CH₃).

10 2-Acetoxyphenyl-hept-2-ynyl sulfide (87) was obtained in 56% yield. ¹H NMR (CDCl₃) δ 7.53-7.56 (dd, 1 H, ArH), 7.22-7.27 (m, 2 H, ArH), 7.08-7.09 (dd, 1 H, ArH), 3.57-3.58 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 2.13-2.17 (m, 2 H, CH₂), 1.32-1.45 (m, 4 H, CH₂), 15 0.85-0.89 (t, 3 H, CH₃).

2-Acetoxyphenylhex-2-ynyl sulfide (88) was obtained in 56% yield. ¹H NMR (CDCl₃) δ 7.53-7.56 (dd, 1 H, ArH), 7.22-7.27 (m, 2 H, ArH), 7.06-7.09 (dd, 1 H, ArH), 3.57-3.59 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 2.10-2.16 (m, 2 H, CH₂), 1.43-1.51 (q, 2 H, CH₂), 20 0.89-0.94 (t, 3 H, CH₃).

2-Acetoxyphenylpent-2-ynyl sulfide (89) was obtained in 63% yield. ¹H NMR (CDCl₃) δ 7.53-7.56 (dd, 1 H, ArH), 7.22-7.27 (m, 2 H, ArH), 7.06-7.09 (dd, 1 H, ArH), 3.57-3.59 (t, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 2.10-2.16 (m, 2 H, CH₂), 0.89-0.94 (t, 3 H, CH₃).

25 2-Acetoxyphenyl-but-2-ynyl sulfide (90) was obtained in 78% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.52-7.54 (dd, 1 H, ArH), 7.2-7.29 (m, 2 H, ArH), 7.06-7.09 (dd, 1 H, ArH), 3.55-3.56 (d, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.8 (s, 3 H, CH₃).

30 2-Acetoxyphenyl-prop-2-ynyl sulfide (91) was obtained in 58% yield (Figure 2G). ¹H NMR (CDCl₃) δ 7.56-7.59 (dd, 1 H, ArH), 7.22-7.33 (m, 2 H, ArH), 7.08-7.11 (dd, 1 H, ArH), 3.56-3.57 (d, 2 H, CH₂), 2.35 (s, 3 H, CH₃), 2.22-2.24 (t, 1 H, CH).

EXAMPLE 26

35

Compound 97

¹H NMR spectrum and FAB-MS of the oil obtained following chromatography indicated acetylation had not taken place, instead cyclization had occurred to afford compound 85 in

81% yield. ^1H NMR (CDCl_3) δ 7.22-7.33 (m, 2 H, ArH), 7.07-7.12 (m, 2 H, ArH), 3.5-3.57 (q, 1 H, CH), 1.52-1.59 (d, 3 H, CH_3); FAB-MS 181 (MH^+ , 20), 180 (M^+ , 22), 157 (28), 132 (20), 79 (100).

5

EXAMPLE 27

Enzymology

Sheep seminal vesicles were purchased from Oxford Biomedical Research, Inc. (Oxford, MI). Arachdonic acid was purchased from Nu Chek Prep (Elysian, MN). Hematin, hydrogen peroxide, and guaiacol were purchased from Sigma Chemical Co. (St. Louis, MO). PGHS-1 was purified from sheep seminal vesicles as described earlier. The specific activity of the protein was 20.9 ($\mu\text{MO}_2/\text{min}$)/mg, and the percentage of holoenzyme was 13.5%. ApoPGHS was prepared as described earlier. Apoenzyme was reconstituted by the addition of hematin to the assay mixtures. Human PGHS-2 (1.62 $\mu\text{g}/\mu\text{l}$) was obtained from J. Gierse, Monsanto (St. Louis, MO).

10

15

EXAMPLE 28

Cyclooxygenase Activity

Oxygen consumption was measured at 37°C with a Gilson model 5/6 oxygraph (Gilson Medical Electronics, Inc., Middleton, WI) equipped with a Clark electrode and a thermostated cuvette. Enzyme aliquots (0.16 μM) were added to 100 mM Tris-HCl at pH 8.0 containing 500 μM phenol and 1 μM hematin in a final volume of 1.3 mL. Oxygen uptake was initiated by the addition of 100 μM sodium arachidonate, and the initial reaction velocity was determined from the linear portion of the oxygen uptake curve.

20

30

EXAMPLE 29

Peroxidase Activity

Assays were performed at 25°C on a Shimadzu UV 160U by measuring the initial rates of oxidation of guaiacol at 436 nm. Enzyme aliquots (0.16 μM) were added to 100 mM Tris-HCl (pH 8) containing 1 μM heme and 500 μM guaiacol in 1 mL disposable cuvettes. Reaction was initiated by the addition of 400 μM hydrogen peroxide.

35

EXAMPLE 30

Time-Dependent Inhibition of the Cyclooxygenase and Peroxidase Activity of Apo and HoloPGHS-1 and PGHS-2 Using the Oxygen Uptake Assay

5 ApoPGHS-1 (2.48 $\mu\text{g}/\mu\text{l}$) (5 μM) or apoPGHS-2 (1.62 $\mu\text{g}/\mu\text{l}$) (5 μM) in 100 mM Tris buffer, pH 8.0 containing 500 μM phenol was treated with inhibitor and incubated at room temperature (Figure 4). Periodically, 0.16 μM apoPGHS-1 or apoPGHS-2 aliquots were analyzed for remaining cyclooxygenase activity or peroxidase activity as described. In a similar fashion apoPGHS-1 or apoPGHS-2 (5 μM) in 100 mM Tris buffer, pH 8.0 containing 500 μM phenol was treated with 2 equivalents of hematin (500 μM stock solution in DMSO) and then treated with inhibitor and incubated at room temperature. Periodically, 0.16 μM apoPGHS-1 or apoPGHS-2 aliquots were analyzed for remaining cyclooxygenase activity or peroxidase activity (Figure 4).

EXAMPLE 31

Dependence of pH on the Time-Dependent Inhibition of the Cyclooxygenase Activity of HoloPGHS-2 by 2-Acetoxythioanisole (2) and 2-Acetoxyphenylheptyl sulfide (54) Using the Oxygen Uptake Assay: Comparison With Aspirin

20 ApoPGHS-2 (1.62 $\mu\text{g}/\mu\text{l}$) (5 μM) in 100 mM sodium phosphate buffer, at pH 6, 7, 8, and 9 containing 500 μM phenol was treated with inhibitor (2-acetoxythioanisole 10 mM; 2-acetoxyphenylheptylsulfide 181 μM , or aspirin 32 μM) and incubated at room temperature. Periodically, 0.16 μM apoPGHS-1 or apoPGHS-2 aliquots were analyzed for remaining cyclooxygenase activity or peroxidase activity as described. Figure 5 shows that aspirin had a greater inhibitory effect on PGHS-1 than PGHS-2. Figure 7 shows that 2-acetoxythioanisole greatly inhibited cyclooxygenase activity of holoPGHS-2 at pH 9.

EXAMPLE 32

Time- and Concentration-Dependent Inhibition of Ovine PGHS-1 and human PGHS-2 Using the Thin Layer Chromatography Assay

35 Cyclooxygenase activity of ovine PGHS-1 (22 nM) or human PGHS-2 (88 nM) was assayed by TLC. Reaction mixtures of 200 μL consisted of hematin-reconstituted protein in 100 mM

Tris-HCl, pH 8.0, 500 μ M phenol, and [1- 14 C]arachidonic acid (50 μ M, 57 mCi/mmol). For the time-dependent inhibition assay, hematin-reconstituted PGHS-1 (22 nM) or PGHS-2 (88 nM) was preincubated at room temperature for 2 hours and then at 0°C for 1 hour with varying concentrations of inhibitor in DMSO followed by the addition of [1- 14 C]arachidonic acid (50 μ M) for 30 seconds at 37°C. Reactions were terminated by solvent extraction in diethyl ether/methanol/1 M citrate, pH 4.0 (30:4:1). The organic phase was spotted on a TLC plate (Amersham Corp.). The plate was developed with ethyl acetate/methylene chloride/glacial acetic acid (75:25:1) at 4°C. Radiolabeled products were quantitated with a radioactivity scanner (Bioscan, Inc., Washington, D. C.). The conversion of arachidonic acid to products was linear with respect to both protein content and incubation time. The percentage of total products observed at different inhibitor concentrations was divided by the percentage of total products observed for protein samples preincubated for the same time with DMSO. Figure 8 shows that 0.1 mM of compound 6 inhibited about 35% of human PGHS-2.

EXAMPLE 33

Inactivation of the Cyclooxygenase Activity of Apo- and HoloPGHS-2 by 2-Acetoxy-1-thioanisole and Reactivation by Hydroxylamine

ApoPGHS-2 (5 μ M) or apoPGHS-2 (5 μ M), reconstituted with 2 equivalents of hematin in 100 mM Tris-HCl, pH 8 at 37°C containing 500 μ M phenol was treated with 2-acetoxy-1-thioanisole (10 mM). Periodically, 0.16 μ M enzyme aliquots were analyzed for remaining cyclooxygenase activity as described earlier. The cyclooxygenase activity was inhibited by greater than 70% in 2.5 hours. Hydroxylamine hydrochloride (80 mM) in 10 mM Tris-HCl, pH 7.5 was then added to the incubation mixture and 0.16 μ M enzyme aliquots were analyzed for reactivation of the inhibited cyclooxygenase-2. A similar reactivation experiment was performed with N-acetylimidazole which inhibits the cyclooxygenase activity of apoPGHS-1 and following addition of hydroxyl amine, the enzyme activity is regenerated. (Figure 6).

EXAMPLE 34Synthesis of 2-[1-¹⁴C]-acetoxythioanisole (¹⁴C-2)

A reaction mixture containing 2-hydroxythioanisole (1, 3 mg, 21 μ mol) in 300 μ L of CH_2Cl_2 was treated with dry pyridine (2.85 μ L, 36 μ mol) and allowed to stir at room temperature for 5 minutes. CH_2Cl_2 (200 μ L each) was added to the vials containing [1-¹⁴C]-acetic anhydride (3 μ L of total radiolabeled substance in two vials) (3 μ L, 31 μ mol, 55 mCi/mmol) and this mixture was transferred via a syringe to the reaction mixture. The vials containing the radiolabeled material were washed with an additional 200 μ L of CH_2Cl_2 and these washings were transferred to the reaction mixture as well. The reaction mixture was stirred overnight at room temperature. The reaction mixture was then loaded on a silica gel column and eluted with EtOAc:hexanes (1:99). At this solvent polarity, unreacted starting material eluted out. The polarity of the solvent was then increased (EtOAc:hexanes; 3:97) and the more polar radiolabeled 2-acetoxythioanisole eluted out (1 mg, 35% yield based on starting 2-hydroxythioanisole). TLC (EtOAc:hexanes; 10:90) single spot (R_f = 0.625); specific activity 55 mCi/mmol.

EXAMPLE 35Synthesis of 2-[1-¹⁴C]-acetoxyphenylhept-2-ynyl sulfide (¹⁴C-79)

A reaction mixture containing 2-hydroxyphenyl hept-2-ynyl sulfide (78, 4 mg, 18 μ mol) in 300 μ L of CH_2Cl_2 was treated with dry pyridine (2.4 μ L, 30 μ mol) and allowed to stir at room temperature for 5 min. CH_2Cl_2 (200 μ L x 2) was added to the vial containing [1-¹⁴C]-acetic anhydride (3 μ L, 31 μ mol, 55 mCi/mmol) and this mixture was transferred via a syringe to the reaction mixture. The reaction mixture was stirred overnight at room temperature. The reaction mixture was then loaded on a silica gel column and eluted with EtOAc:hexanes (2:98) to afford ¹⁴C-79. (1 mg, 10% yield based on starting phenol). TLC (EtOAc:hexanes; 10:90) single spot (R_f = 0.6); specific activity 55 mCi/mmol.

EXAMPLE 36Inhibition of Activated RAW264.7 Cells by 2-Acetoxy-1-thioanisole, 2-Acetoxyphenylheptyl sulfide, and Aspirin

The murine macrophage cell line RAW264.7 were seeded overnight for 30% confluency the following morning.

Overnight DMEM and fetal bovine serum (FBS) was removed and 2 mL DMEM containing 1.5% FBS \pm 500 ng/mL LPS and 10 units/mL interferon- γ were added for 7.5 hours at 37°C. Activation medium was removed and 2.0 mL SF-DMEM and/or aspirin or 2-acetoxyphenylheptyl sulfide (54) at varying concentrations were added for 30 min at 37 °C. Arachidonic acid metabolism was measured by adding 20 μ M 14C-AA for 15 min at room temperature. Aliquots (200 μ L) were removed into termination solution and run on TLC plates. In the case of 2-acetoxythioanisole (2), following 8 hours of activation, 500 μ M 2 was added for the next 3.5 hours. After 11.5 hours of activation, 20 μ M [1-¹⁴C]arachidonic acid was incubated with the cells for 20 minutes at room temperature, and total products were determined by TLC.

Figure 9 shows that compound 54 greatly inhibited cyclooxygenase activity of human holoPGHS-2 whereas compound 38 had very little effect. Figure 10 shows the pH dependency of the effect of compound 54 on cyclooxygenase activity of human holoPGHS-2 with the greatest inhibition seen at pH 9. Figure 11 shows that 8 μ M of compound 67 greatly inhibited cyclooxygenase activity of human holoPGHS-2 where as compound 71 had very little effect. Figure 12 shows that 1-16 μ M compound 79 greatly inhibited cyclooxygenase activity of human holoPGHS-2 where as compound 78 had very little effect. Figure 13 shows that compound 2 greatly inhibited cyclooxygenase activity of human holoPGHS-2 in activated macrophages. Figure 14 shows that compound 54 had a greater inhibitory effect on PGHS-2 in activated macrophages than aspirin. Figure 15 shows that compounds 54 and 79 both greatly inhibited cyclooxygenase activity of human holoPGHS-2 in activated macrophages.

TABLE 1 shows the time and concentration-dependent inhibition of PGHS-2 and PGHS-1 by 2-acyloxyphenylalkyl and aryl sulfides, including compounds 6, 7, 8, 59, 60, 61, 62, 63 and 93. TABLE 2 shows the time and concentration-dependent inhibition of PGHS-2 and PGHS-1 by 2-acyloxyphenylalkyl and aryl sulfides, including compounds 2, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 67, 71, 75, 79, 83 and 87.

TABLE 1

Time- and Concentration-Dependent Inhibition of PGHS-2 and PGHS-1 by
2-Acyloxyphenylalkyl-, cycloalkyl-,oxoalkyl-, and alkenyl Sulfides.

5	Cmpd	R	IC ₅₀ , μ M	IC ₅₀ , μ M	IC ₅₀ (PGHS-1)
			(PGHS-2) ^a	(PGHS-1)	/IC ₅₀ (PGHS-2)
10	2	CH ₃	250	>5mM	>100
	49	CH ₂ CH ₃	200	375	1.8
	50	(CH ₂) ₂ CH ₃	66	66	1.0
	51	(CH ₂) ₃ CH ₃	40	34	1.2
	52	(CH ₂) ₄ CH ₃	5	5	1.0
15	53	(CH ₂) ₅ CH ₃	3.5	8	2.3
	54	(CH ₂) ₆ CH ₃	2*	6	3
	55	(CH ₂) ₇ CH ₃	---b	---b	---
	56	(CH ₂) ₈ CH ₃	---b	---b	---
	57	cyclohexyl	---b	---b,c	---
20	58	cycloheptyl	---b	---b	---
	67	(CH ₂) ₂ O(CH ₂) ₃ CH ₃	7	22	3
	71	(CH ₂) ₃ O(CH ₂) ₃ CH ₃	---b	---b	---
	75	CH ₂ CH=CH(CH ₂) ₃ CH ₃	11	---d	---

^aIncubations of inhibitors with PGHS-2 (88 nM) or PGHS-1 (22 nM) were conducted at room temperature for 3 hours. The cyclooxygenase reaction was initiated by the addition of ¹⁴C-arachidonic acid (50 μ M) to the incubation mixtures at 37°C for 30 sec. ^bNo significant inhibition discernible at the concentrations ranges (1 μ M to 33 mM) studied. ^c~25-30% inhibition of PGHS-1 at these concentrations. ^{*}The corresponding phenol 38 did not inhibit PGHS-1 or PGHS-2; the sulfone 93 was a very poor inhibitor of either isozyme and did not display any selectivity. ^d~25% inhibition of PGHS-1 by 75 at 16.5 μ M.

TABLE 2

Time- and Concentration-Dependent Inhibition of PGHS-2 and PGHS-1 by
 5 2-Acetoxyphenylalkyl and aryl Sulfides.

	Cmpnd	R	IC ₅₀ , μM	IC ₅₀ , μM	IC ₅₀ (PGHS-1)
			(PGHS-2) ^a	(PGHS-1)	/IC ₅₀ (PGHS-2)
10	87	CH ₂ CH≡C(CH ₂) ₃ CH ₃	0.8 ^b	>17	21
	88	CH ₂ C≡C(CH ₂) ₂ CH ₃	3	14	4.6
	89	CH ₂ C≡CCH ₂ CH ₃	5	20	4
15	90	CH ₂ C≡CCH ₃	20	>35	>2
	91	CH ₂ C≡CH	25	40	1.6

20 ^a Incubations of inhibitors with PGHS-2 (88 nM) or PGHS-1 (22 nM) were conducted at room temperature for 3 hours. The cyclooxygenase reaction was initiated by the addition of ¹⁴C-arachidonic acid (50 μM) to the incubation mixtures at 37°C for 30 sec. ^bThe corresponding phenol 82 did not inhibit PGHS-1 or PGHS-2.

TABLE 3

Time and Concentration-Dependent Inhibition of PGHS-2 and PGHS-1 by 2-acetoxyphenylalkyl and aryl sulfides

5	Compound	R	R'	IC ₅₀ , μ M	IC ₅₀ , μ M
				PGHS-2 ^a	PGHS-1
	6	CH ₃	CF ₃	260	260
	7	CH ₃	CH ₂ Cl	360	390
10	8	CH ₃	CH ₂ Br	510	320
	59	CH ₂ Ph	CH ₃	250	>400 ^b
	60	(CH ₂) ₂ Ph	CH ₃	100	>150 ^b
	61	(CH ₂) ₃ Ph	CH ₃	--- ^c	--- ^c
	62	(CH ₂) ₃ OPh	CH ₃	--- ^c	--- ^c
15	63	(CH ₂) ₇ COOH	CH ₃	--- ^c	>1 mMd
	97	-----	-----	--- ^c	--- ^c

^a Incubations of inhibitors with PGHS-2 (88 nM) or PGHS-1 (22 nM) were conducted at room temperature for 3 hours. The cyclooxygenase reaction was initiated by the addition of ¹⁴C-arachidonic acid (50 μ M) to the incubation mixtures at 37 C for 30 seconds. ^b 25-30% inhibition of PGHS-1 at these concentrations. ^c No significant inhibition discernible at

the concentration ranges studies (66 μ M to 1 mM). ^{*} ~30% inhibition of PGHS-1 at 1 mM. The fluoroacetoxythioanisole analogs 24 and 31 as well as the aspirin analog 19 did not display significant inhibition of either isozyme. Increments in the length of the acyl group (compounds 9-14) led to inactive compounds.

The following references were cited herein:

- 30 (1) Hla, T., Neilson, K. Human Cyclooxygenase-2 cDNA. *Proc. Natl. Acad. Sci. U. S. A.* 1992, 89, 7384-7388.
- (2) Xie, W., Chipman, J. G., Robertson, D. L., Erickson, R. L., Simmons, D. L. Expression of a Mitogen-Response Gene Encoding Prostaglandin Synthase is Regulated mRNA splicing. *Proc. Natl. Acad. Sci. U. S. A.* 1991, 88, 2692-2696.
- 35 (3) Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., Herschman, H. R. TIS10, a Phorbol Ester Tumor Promoter-Inducible mRNA From Swiss 3T3 Cells, Encodes a Novel

- Prostaglandin Synthase/Cyclooxygenase Homologue. *J. Biol. Chem.* 1991, 266, 12866-12872.
- (4) Masferrer, J. L., Seibert, K., Zweifel, B., Needleman, P. Endogenous Glucocorticoids Regulate an Inducible Cyclooxygenase Enzyme. *Proc. Natl. Acad. Sci. U. S. A.* 1992, 89, 3917-3921.
- 5 (5) Allison, M. C., Howatson, A. G., Torrance, C. J., Lee, F. D., Russell, R. I. G. Gastrointestinal Damage Associated With the Use of Nonsteroidal Antiinflammatory Drugs. *N. Engl. J. Med.* 1992, 327, 749-754.
- 10 (6) Clive, D. M., Stoff, J. S. Renal Syndromes Associated With Nonsteroidal Antiinflammatory Drugs. *N. Engl. J. Med.* 1984, 310, 563-572.
- (7) Pirson, Y., Van Ypersele de Strihou, C. Renal Side Effects of Nonsteroidal Antiinflammatory Drugs: Clinical Relevance. *Am. J. Kidney Dis.* 1986, 8, 337-344.
- 15 (8) Futaki, N., Yoshikawa, K., Hamasaka, Y., Arai, I., Higuchi, S., Iizuka, H., Otomo, S. NS-398, A Novel Nonsteroidal Antiinflammatory Drug With Potent Analgesic and Antipyretic Effects, Which Causes Minimal Stomach Lesions. *Gen. Pharmacol.* 20 1993, 24, 105-110.
- (9) Futaki, N., Takahashi, S., Yokoyama, M., Arai, I., Higuchi, S., Otomo, S. NS-398, A New Anti-Inflammatory Agent, Selectively Inhibits Prostaglandin G/H Synthase/Cyclooxygenase (COX-2) Activity In Vitro. *Prostaglandins* 1994, 47, 55-59.
- 25 (10) Li, C-S., Black, W. C., Chan, C-C., Ford-Hutchinson, A. W., Gauthier, J-Y., Gordon, R., Guay, D., Kargman, S., Lau, C. K., Mancini, J., Quimet, N., Roy, P., Vickers, P., Wong, E., Young, R. N., Zamboni, R., Prasit, P. Cyclooxygenase-2 Inhibitors. Synthesis and Pharmacological Activities of 5-Methanesulfonamido-1-indanone Derivatives. *J. Med. Chem.* 1995, 38, 4897-4905.
- 30 (11) Huff, R., Collins, P., Kramer, S., Seibert, K., Koboldt, C., Gregory, S., Isakson, P. A Structural Feature of N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide (NS-398) That Governs its Selectivity and Affinity for Cyclooxygenase 2 (COX2). *Inflamm. Res.* 1995, 44:Suppl. 2, S145-S146.
- 35 (12) Gan, K. R., Galbraith, W., Roman, R. J., Haber, S. B., Kerr, J. S., Schmidt, W. K., Smith, C., Hewes, W. E., Ackerman, N. R. Anti-Inflammatory and Safety Profile of DuP 697, a Novel Orally

Effective Prostaglandin Synthesis Inhibitor. *J. Pharmacol. Exp. Ther.* 1990, 254, 180-187.


- (13) Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, P., William, L. L., Isakson, P. C. Pharmacological and Biochemical
5 Demonstration of the Role of Cyclooxygenase-2 in Inflammation. *Proc. Natl. Acad. Sci. U. S. A.* 1994, 91, 12013-12017.
- (14) Kalgutkar, A. S., Crews, B. C., Marnett, L. J. Kinetics of the Interaction of Nonsteroidal Anti-inflammatory Drugs With Prostaglandin Endoperoxide Synthase-1 Studied by Limited
10 Proteolysis. *Biochemistry* 1996, 35, 9076-9082.
- (15) Li, J. J., Norton, M. B., Reinhard, E. J., Anderson, G. D., Gregory, S. A., Isakson, P. C., Koboldt, C. M., Masferrer, J. L., Perkins, W. E., Seibert, K., Zhang, Y., Zweifel, B. S., Reitz, D. B. Novel Terphenyls as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-
15 Inflammatory Agents. *J. Med. Chem.* 1996, 39, 1846-1856.

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications
20 are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and
25 obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations
30 on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

WHAT IS CLAIMED IS:

1. A compound of the formula



(I)

wherein R is selected from the group consisting of CH₃, CH₂CH₃, (CH₂)₂CH₃, (CH₂)₃CH₃, (CH₂)₄CH₃, (CH₂)₅CH₃, (CH₂)₆CH₃, (CH₂)₂O(CH₂)₃CH₃, CH₂HC=CH(CH₂)₃CH₃, CH₂C≡C(CH₂)₃CH₃, CCH₂C≡C(CH₂)₂CH₃, CH₂C≡C-CCH₂CH₃, CH₂C≡C-CH₃ and CH₂C≡CH; and

R' is selected from the group consisting of CH₃, CF₃, CH₂Cl and CH₂Br or a pharmaceutically acceptable salt or hydrate thereof.

2. The compound of claim 1 which is 2-acetoxythioanisole, or a pharmaceutically acceptable salt or hydrate thereof.

3. The compound of claim 1 which is 2-(trifluoromethylacetoxy)thioanisole, or a pharmaceutically acceptable salt or hydrate thereof.

4. The compound of claim 1 which is 2-(α-chloroacetoxy)thioanisole or a pharmaceutically acceptable salt or hydrate thereof.

5. The compound of claim 1 which is 2-(α-bromoacetoxy)thioanisole, or a pharmaceutically acceptable salt or hydrate thereof.

6. The compound of claim 1 which is 2-acetoxyphenylbenzyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

5 7. The compound of claim 1 which is 2-acetoxyphenyl-2-phenylethyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

10 8. The compound of claim 1, which is 2-acetoxyphenylethyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

15 9. The compound of claim 1, which is 2-acetoxyphenylpropyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

20 10. The compound of claim 1, which is 2-acetoxyphenylbutyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

11. The compound of claim 1, which is 2-acetoxyphenylpentyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

25 12. The compound of claim 1, which is 2-acetoxyphenylhexyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

30 13. The compound of claim 1, which is 2-acetoxyphenylheptyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

35 14. The compound of claim 1, which is 2-acetoxyphenyl-2-butoxyethyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

15. The compound of claim 1, which is 2-Acetoxyphenyl-2-*trans*-heptenyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

16. The compound of claim 1, which is 2-acetoxyphenylhept-2-ynyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

5

17. The compound of claim 1, which is 2-acetoxyphenylhex-2-ynyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

10

18. The compound of claim 1, which is 2-acetoxyphenylpent-2-ynyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

15

19. The compound of claim 1, which is 2-acetoxyphenylbut-2-ynyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

20

20. The compound of claim 1, which is 2-acetoxyphenylprop-2-ynyl sulfide, or a pharmaceutically acceptable salt or hydrate thereof.

25

21. A method of inhibiting the synthesis of prostaglandin endoperoxide synthase-2 (PGHS-2) in a mammal in need of such treatment, comprising the step of administering to said mammal an effective amount of a compound of Formula (I) of claim 1.

30

22. The method of claim 21, wherein inhibition of prostaglandin endoperoxide synthase-2 is useful in the prophylaxis or therapeutic treatment of edema, fever, algesia, neuromuscular pain, headache, cancer pain or arthritic pain.

35

23. The method of claim 11, wherein said compound is selected from the group consisting of 2-acetoxythioanisole, 2-(trifluoromethylacetoxy)thioanisole, 2-(α -chloroacetoxy)thioanisole, 2-(α -bromoacetoxy)thioanisole, 2-acetoxyphenylbenzyl sulfide, 2-acetoxyphenyl-2-phenylethyl sulfide, 2-acetoxyphenylethyl sulfide, 2-acetoxyphenylpropyl

sulfide, 2-acetoxyphenylbutyl sulfide, 2-acetoxyphenylpentyl sulfide, 2-acetoxyphenylhexyl sulfide, 2-acetoxyphenylheptyl sulfide, 2-acetoxyphenyl-2-butoxyethyl sulfide, 2-acetoxyphenyl-2-*trans*-heptenyl sulfide, 2-acetoxyphenylhept-2-ynyl sulfide, 2-acetoxyphenylhex-2-ynyl sulfide, 2-acetoxyphenylpent-2-ynyl sulfide, 2-acetoxyphenylbut-2-ynyl sulfide and 2-acetoxyphenylprop-2-ynyl sulfide, or pharmaceutically acceptable salts or hydrates thereof.

10

24. A pharmaceutical composition, comprising a compound of Formula (I) of claim 1 and a pharmaceutically acceptable carrier or diluent.

15

25. The pharmaceutical composition of claim 24, wherein said compound is selected from the group consisting of 2-acetoxythioanisole, 2-(trifluoromethylacetoxy)thioanisole, 2-(α -chloroacetoxy)thioanisole, 2-(α -bromoacetoxy)thioanisole, 2-acetoxyphenylbenzyl sulfide, 2-acetoxyphenyl-2-phenylethyl sulfide, 2-acetoxyphenylethyl sulfide, 2-acetoxyphenylpropyl sulfide, 2-acetoxyphenylbutyl sulfide, 2-acetoxyphenylpentyl sulfide, 2-acetoxyphenylhexyl sulfide, 2-acetoxyphenylheptyl sulfide, 2-acetoxyphenyl-2-butoxyethyl sulfide, 2-acetoxyphenyl-2-*trans*-heptenyl sulfide, 2-acetoxyphenylhept-2-ynyl sulfide, 2-acetoxyphenylhex-2-ynyl sulfide, 2-acetoxyphenylpent-2-ynyl sulfide, 2-acetoxyphenylbut-2-ynyl sulfide and 2-acetoxyphenylprop-2-ynyl sulfide, or pharmaceutically acceptable salts or hydrates thereof.

20

25







Figure 1




DuP 697




R = SCH₃; SC 8076 (PGHS-1 selective)
R = SO₂CH₃; SC 8092 (PGHS-2 selective)



NS-398



Flosulide, CGP 28238



Aspirin

Figure 2 A




Figure 2B




Figure 2C




Figure 20

6/25




Figure 2E




Figure 2F




Figure 2G




Figure 2H




Figure 2I




Figure 25




Figure 2K




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11





Figure 12




Figure 13

**Inhibition of PGHS-2 in Activated Macrophages
by 2-Acetoxythioanisole (2): Comparison With Aspirin**




Figure 14

Inhibition of PGHS-2 in Activated Macrophages by
2-(Acetoxyphenyl) hept-2-ynyl Sulfide (87) and 2-(Acetoxyphenyl)heptyl Sulfide (54).




Figure 15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/24203

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07C 205/00, 67/02

US CL : 560/125, 254

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 560/125, 254

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS

search terms: structure seach, ihibition

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database CAPLUS on STN, No. 120:54523, ARNOLDI et al., 'Isovanillyl sweeteners. Synthesis and sweet taste of sulfur heterocycles', J. Chem. Soc., Perkin Trans. 1 (1993), 12, 1359-66, abstract.	1-20, 24, 25
X	Database CAPLUS on STN, No. 113:5802, POIRIER et al., 'Preparation of phenolic sulfides. Carbon-13 NMR studies', Sulfur Lett. (1988), 10 (3-4), 169-73, abstract.	1-20, 24, 25
X	Database CAPLUS on STN, No. 99:87741, OHTSUKA et al., 'Medium-ring ketone synthesis. Intramolecular acylation of sulfur-stabilized carbanions: a model study', Chem. Pharm. Bull. (1983), 31(2), 443-53, abstract.	1-20, 24, 25
Y	Database CAPLUS on STN, No. 106:148957, DUPIN et al., 'Acetoxybenzene derivatives: in vitro antiaggregant activity', Farmaco, Ed. Sci. (1986), 41(12), 934-41, abstract.	1-25

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

02 MARCH 1998

Date of mailing of the international search report

14 APR 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231.

Facsimile N. (703) 305-3230

Authorized officer

BRIAN J. DAVIS

Telephone No. (703) 308-1235